Cover
Cover - USD ($) | 12 Months Ended | ||
Dec. 31, 2021 | Feb. 21, 2022 | Jun. 30, 2021 | |
Cover [Abstract] | |||
Document Type | 10-K | ||
Document Annual Report | true | ||
Document Period End Date | Dec. 31, 2021 | ||
Current Fiscal Year End Date | --12-31 | ||
Document Transition Report | false | ||
Entity File Number | 001-37565 | ||
Entity Registrant Name | NovoCure Limited | ||
Entity Incorporation, State or Country Code | Y9 | ||
Entity Tax Identification Number | 98-1057807 | ||
Entity Address, Address Line One | No. 4 The Forum | ||
Entity Address, Address Line Two | Grenville Street | ||
Entity Address, City or Town | St. Helier | ||
Entity Address, Country | JE | ||
Entity Address, Postal Zip Code | JE2 4UF | ||
Country Region | +44 | ||
City Area Code | (0) 15 | ||
Local Phone Number | 3475 6700 | ||
Title of 12(b) Security | Ordinary shares, no par value per share | ||
Trading Symbol | NVCR | ||
Security Exchange Name | NASDAQ | ||
Entity Well-known Seasoned Issuer | Yes | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Large Accelerated Filer | ||
Entity Small Business | false | ||
Entity Emerging Growth Company | false | ||
ICFR Auditor Attestation Flag | true | ||
Entity Shell Company | false | ||
Entity Public Float | $ 9,486,344,138 | ||
Entity Common Stock, Shares Outstanding | 104,419,377 | ||
Documents Incorporated by Reference | Portions of the registrant’s definitive proxy statement for its 2022 annual meeting of shareholders are incorporated by reference into Items 10, 11, 12, 13, and 14 of Part III of this Form 10-K. Such definitive proxy statement will be filed with the Securities and Exchange Commission within 120 days after the end of the registrant’s fiscal year ended December 31, 2021. | ||
Amendment Flag | false | ||
Document Fiscal Year Focus | 2021 | ||
Document Fiscal Period Focus | FY | ||
Entity Central Index Key | 0001645113 |
Audit Information
Audit Information | 12 Months Ended |
Dec. 31, 2021 | |
Audit Information [Abstract] | |
Auditor Firm ID | 1281 |
Auditor Name | KOST FORER GABBAY & KASIERERA Member of Ernst & Young Global |
Auditor Location | Israel |
Consolidated balance sheets
Consolidated balance sheets - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Current assets: | ||
Cash and cash equivalents | $ 208,802 | $ 234,674 |
Short-term investments | 728,898 | 607,902 |
Restricted cash | 807 | 11,499 |
Trade receivables, net | 93,567 | 96,699 |
Receivables and prepaid expenses | 17,025 | 21,245 |
Inventories | 24,427 | 27,422 |
Total current assets | 1,073,526 | 999,441 |
Long-term assets: | ||
Property and equipment, net | 22,693 | 11,395 |
Field equipment, net | 12,923 | 11,230 |
Right-of-use assets | 18,267 | 19,009 |
Other long-term assets | 12,086 | 10,908 |
Total long-term assets | 65,969 | 52,542 |
Total assets | 1,139,495 | 1,051,983 |
Current liabilities: | ||
Trade payables | 72,600 | 53,647 |
Other payables, lease liabilities and accrued expenses | 70,002 | 59,965 |
Total current liabilities | 142,602 | 113,612 |
Long-term liabilities: | ||
Long-term debt, net | 562,216 | 429,905 |
Deferred revenues | 6,477 | 12,139 |
Long term leases | 12,997 | 14,293 |
Employee benefit liabilities | 4,543 | 5,171 |
Other long-term liabilities | 166 | 337 |
Total long-term liabilities | 586,399 | 461,845 |
Total liabilities | 729,001 | 575,457 |
Commitments and contingencies | ||
Shareholders’ equity: | ||
Ordinary shares - No par value, Unlimited shares authorized; Issued and outstanding: 103,971,263 shares and 102,334,276 shares at December 31, 2021 and December 31, 2020 respectively; | 0 | 0 |
Additional paid-in capital | 1,099,589 | 1,111,435 |
Accumulated other comprehensive income (loss) | (3,169) | (3,832) |
Retained earnings (accumulated deficit) | (685,926) | (631,077) |
Total shareholders’ equity | 410,494 | 476,526 |
Total liabilities and shareholders’ equity | $ 1,139,495 | $ 1,051,983 |
Consolidated balance sheets (Pa
Consolidated balance sheets (Parenthetical) - shares | Dec. 31, 2021 | Dec. 31, 2020 |
Statement of Financial Position [Abstract] | ||
Common stock issued (in shares) | 103,971,263 | 102,334,276 |
Common stock outstanding (in shares) | 103,971,263 | 102,334,276 |
Consolidated statements of oper
Consolidated statements of operations - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Income Statement [Abstract] | |||
Net revenues | $ 535,031 | $ 494,366 | $ 351,318 |
Cost of revenues | 114,877 | 106,501 | 88,606 |
Gross profit | 420,154 | 387,865 | 262,712 |
Operating costs and expenses: | |||
Research, development and clinical studies | 201,303 | 132,010 | 79,003 |
Sales and marketing | 137,057 | 118,017 | 96,675 |
General and administrative | 126,127 | 107,437 | 87,948 |
Total operating costs and expenses | 464,487 | 357,464 | 263,626 |
Operating income (loss) | (44,333) | 30,401 | (914) |
Financial expenses (income), net | 7,742 | 12,299 | 7,910 |
Income (loss) before income taxes | (52,075) | 18,102 | (8,824) |
Income tax | 6,276 | (1,706) | (1,594) |
Net income (loss) | $ (58,351) | $ 19,808 | $ (7,230) |
Basic net income (loss) per ordinary share (in usd per share) | $ (0.56) | $ 0.20 | $ (0.07) |
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares) | 103,433,274 | 100,930,866 | 97,237,549 |
Diluted net income (loss) per ordinary share (in usd per share) | $ (0.56) | $ 0.18 | $ (0.07) |
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares) | 103,433,274 | 108,877,648 | 97,237,549 |
Consolidated statements of comp
Consolidated statements of comprehensive income (loss) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Statement of Comprehensive Income [Abstract] | |||
Net income (loss) | $ (58,351) | $ 19,808 | $ (7,230) |
Other comprehensive income (loss), net of tax : | |||
Change in foreign currency translation adjustments | 302 | (85) | (304) |
Pension benefit plan | 361 | (980) | (1,063) |
Total comprehensive income (loss) | $ (57,688) | $ 18,743 | $ (8,597) |
Statements of changes in shareh
Statements of changes in shareholders' equity - USD ($) $ in Thousands | Total | Cumulative Effect, Period of Adoption, Adjustment | Ordinary shares | Additional paid-in capital | Additional paid-in capitalCumulative Effect, Period of Adoption, Adjustment | Accumulated other comprehensive income (loss) | Retained earnings (accumulated deficit) | Retained earnings (accumulated deficit)Cumulative Effect, Period of Adoption, Adjustment |
Beginning balance (in shares) at Dec. 31, 2018 | 93,254,185 | |||||||
Beginning balance at Dec. 31, 2018 | $ 112,259 | $ 757,314 | $ (1,400) | $ (643,655) | ||||
Share-based compensation to employees | 52,416 | 52,416 | ||||||
Exercise of options (in shares) | 6,206,884 | |||||||
Exercise of options | 59,245 | 59,245 | ||||||
Issuance of shares in connection with employee stock purchase plan (in shares) | 67,366 | |||||||
Issuance of shares in connection with employee stock purchase plan | 2,467 | 2,467 | ||||||
Other comprehensive income (loss), net of tax (benefit) expense | (1,367) | (1,367) | ||||||
Net income (loss) | (7,230) | (7,230) | ||||||
Ending balance (in shares) at Dec. 31, 2019 | 99,528,435 | |||||||
Ending balance at Dec. 31, 2019 | 217,790 | 871,442 | (2,767) | (650,885) | ||||
Share-based compensation to employees | 75,721 | 75,721 | ||||||
Exercise of options (in shares) | 2,739,150 | |||||||
Exercise of options | 28,428 | 28,428 | ||||||
Issuance of shares in connection with employee stock purchase plan (in shares) | 66,691 | |||||||
Issuance of shares in connection with employee stock purchase plan | 3,370 | 3,370 | ||||||
Conversion feature of convertible note, net | $ 132,474 | 132,474 | ||||||
Accounting Standards Update [Extensible List] | Accounting Standards Update 2020-06 [Member] | |||||||
Other comprehensive income (loss), net of tax (benefit) expense | $ (1,065) | (1,065) | ||||||
Net income (loss) | 19,808 | 19,808 | ||||||
Ending balance (in shares) at Dec. 31, 2020 | 102,334,276 | |||||||
Ending balance at Dec. 31, 2020 | 476,526 | $ (128,972) | 1,111,435 | $ (132,474) | (3,832) | (631,077) | $ 3,502 | |
Share-based compensation to employees | $ 94,900 | 94,900 | ||||||
Exercise of options (in shares) | 1,016,369 | 1,585,617 | ||||||
Exercise of options | $ 21,182 | 21,182 | ||||||
Issuance of shares in connection with employee stock purchase plan (in shares) | 51,370 | |||||||
Issuance of shares in connection with employee stock purchase plan | 4,546 | 4,546 | ||||||
Other comprehensive income (loss), net of tax (benefit) expense | 663 | 663 | ||||||
Net income (loss) | (58,351) | (58,351) | ||||||
Ending balance (in shares) at Dec. 31, 2021 | 103,971,263 | |||||||
Ending balance at Dec. 31, 2021 | $ 410,494 | $ 1,099,589 | $ (3,169) | $ (685,926) |
Statements of changes in shar_2
Statements of changes in shareholders' equity (Parenthetical) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Statement of Stockholders' Equity [Abstract] | |||
Other comprehensive income (loss), tax (benefit) expense | $ 0 | $ 0 | $ (145) |
Consolidated statements of cash
Consolidated statements of cash flows - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Cash flows from operating activities: | |||
Net income (loss) | $ (58,351) | $ 19,808 | $ (7,230) |
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | |||
Depreciation and amortization | 10,251 | 9,150 | 8,460 |
Accrued interest | (94) | 0 | 0 |
Asset write-downs and impairment of field equipment | 649 | 429 | 398 |
Share-based compensation | 94,900 | 75,721 | 52,416 |
Foreign currency remeasurement loss (gain) | 3,231 | (699) | (917) |
Decrease (increase) in accounts receivables | 5,270 | (30,354) | (36,496) |
Amortization of discount (premium) | 3,101 | 3,260 | (2,176) |
Decrease (increase) in inventories | 2,483 | (2,935) | (1,159) |
Decrease (increase) in other long-term assets | 4,519 | (1,366) | 3,446 |
Increase (decrease) in accounts payables and accrued expenses | 27,777 | 25,470 | 16,883 |
Increase (decrease) in other long-term liabilities | (10,980) | 664 | (7,006) |
Net cash provided by (used in) operating activities | 82,756 | 99,148 | 26,620 |
Cash flows from investing activities: | |||
Purchase of property, equipment and field equipment | (24,170) | (14,968) | (10,485) |
Proceeds from maturity of short-term investments | 958,000 | 150,000 | 420,661 |
Purchase of short-term investments | (1,078,664) | (607,879) | (461,843) |
Net cash provided by (used in) investing activities | (144,834) | (472,847) | (51,667) |
Cash flows from financing activities: | |||
Proceeds from issuance of shares, net | 4,546 | 3,370 | 2,467 |
Proceeds from convertible note, net | 0 | 558,439 | 0 |
Repayment of long-term debt | (26) | (150,028) | (31) |
Exercise of options | 21,182 | 28,428 | 59,245 |
Net cash provided by (used in) financing activities | 25,702 | 440,209 | 61,681 |
Effect of exchange rate changes on cash, cash equivalents and restricted cash | (188) | 247 | 26 |
Increase (decrease) in cash, cash equivalents and restricted cash | (36,564) | 66,757 | 36,660 |
Cash, cash equivalents and restricted cash at the beginning of the year | 246,173 | 179,416 | 142,756 |
Cash, cash equivalents and restricted cash at the end of the year | 209,609 | 246,173 | 179,416 |
Cash paid during the year for: | |||
Income taxes paid (refunded), net | 3,110 | (3,261) | 11,241 |
Interest paid | 101 | 8,686 | 13,699 |
Non-cash activities: | |||
Right-of-use assets obtained in exchange for lease liabilities | $ 5,387 | $ 5,617 | $ 22,943 |
Organization
Organization | 12 Months Ended |
Dec. 31, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Organization | Organization NovoCure Limited (including its consolidated subsidiaries, the "Company") was incorporated in the Bailiwick of Jersey and is principally engaged in the development, manufacture and commercialization of Tumor Treating Fields ("TTFields") devices, including Optune and Optune Lua (collectively, our "Products"), for the treatment of solid tumor cancers. The Company currently markets Optune in the United States ("U.S."), Germany, Japan and certain other countries. The Company currently markets Optune Lua in the U.S. and European Union. The Company also has a License and Collaboration Agreement (the "Zai Agreement") with Zai Lab (Shanghai) Co., Ltd. ("Zai") to market Optune in China, Hong Kong, Macau and Taiwan ("Greater China"). See Note 12. During the year ended December 31, 2019, the Company implemented changes to its corporate entity operating structure, including transferring certain intellectual property to its Swiss subsidiary, primarily to align corporate entities with the Company’s evolving operations and business model. |
Basis of presentation and signi
Basis of presentation and significant accounting policies | 12 Months Ended |
Dec. 31, 2021 | |
Accounting Policies [Abstract] | |
Basis of presentation and significant accounting policies | Basis of presentation and significant accounting policies The consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). a. Use of estimates: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions, including those related to contingencies, deferred taxes, tax liabilities, useful-life of field equipment, right-of-use assets and lease liabilities, convertible notes, pension liabilities, revenue recognition, accrued expenses and share-based compensation costs. The Company’s management believes that the estimates, judgment and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of net revenue and expenses during the reporting period. Actual results could differ from those estimates. b. Financial statements in U.S. dollars: The accompanying financial statements have been prepared in U.S. dollars in thousands, except for share and per-share data. The Company finances its operations in U.S. dollars and a substantial portion of its costs and revenues from its primary markets is incurred in U.S. dollars. As such, the Company’s management believes that the U.S. dollar is the currency of the primary economic environment in which NovoCure Limited and certain subsidiaries operate. The Company’s reporting currency is U.S. dollars. Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts maintained in currencies other than the U.S. dollar are re-measured into dollars in accordance with Accounting Standards Codification (ASC) No. 830-10, "Foreign Currency Matters." All transaction gains and losses of the re-measurement of monetary balance sheet items are reflected in the consolidated statements of operations as financial income or expenses, as applicable. For a subsidiary whose functional currency has been determined to be its local currency, assets and liabilities are translated at year-end exchange rates and statement of operations items are translated at average exchange rates prevailing during the year. Such translation adjustments are recorded as a separate component of accumulated other comprehensive income (loss) in shareholders' equity. c. Principles of consolidation: The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Intercompany transactions and balances, including unrealized profits from intercompany sales, have been eliminated upon consolidation. d. Cash equivalents: Cash equivalents are short-term, highly liquid investments that are readily convertible into cash with a maturity of three months or less at the date acquired. e. Short-term investments: The Company accounts for investments in debt securities in accordance with ASC 320, "Investments—Debt and Equity Securities." Management determines the appropriate classification of its investments in marketable debt securities at the time of purchase and reevaluates such determinations at each balance sheet date. For the years ended December 31, 2021 and 2020, all securities are classified as held-to-maturity since the Company has the intent and ability to hold the securities to maturity and, accordingly, debt securities are stated at amortized cost. The amortized cost of held-to-maturity securities is adjusted for amortization of premiums and accretion of discounts to maturity and any credit losses. Such amortization and interest are included in the consolidated statement of operations as financial income or expenses, as appropriate. For the three years ended December 31, 2021, no credit losses have been identified. f. Restricted cash The Company has restricted cash used as security for the use of Company credit cards and cash management, presented in short-term assets. Additionally, the Company has pledged bank deposits to cover bank guarantees related to facility rental agreements, fleet lease agreements and customs payments presented in other long-term assets (see Note 12). g. Trade receivables: The Company’s trade receivables balance contains billed and unbilled commercial activities. The Company records an allowance for credit losses, if identified. The Company periodically reviews its customers’ credit risk and payment history. To date, the Company has not experienced any material credit losses related to counter-party risk. h. Inventories: Inventories are stated at the lower of cost or net realizable value. Cost is determined using the weighted average method. The Company regularly evaluates its ability to realize the value of inventory. If the inventories are deemed damaged, if actual demand for the Company’s devices deteriorates, or if market conditions are less favorable than those projected, inventory write-offs may be required. Inventory write-offs of $1,045, $616 and $310, respectively, were recorded for the years ended December 31, 2021, 2020 and 2019. i. Property and equipment: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following rates: % Computers and laboratory equipment 15 - 33 Office furniture 6 - 33 Production equipment 20 Leasehold improvements Over the shorter of the term of the lease or its useful life Land and assets held within construction in progress are not depreciated. Construction in progress is related to the construction or development of property and equipment that is not yet ready for its intended use. j. Field equipment: Field equipment is stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful life of the field equipment, which was determined to be 18 to 36 months. Field equipment is equipment being utilized under service agreements, and accounted for in accordance with ASC 842 on a monthly basis as an operating lease (see Note 2(x)). The Company records a write-off provision for any excess, lost or damaged equipment when warranted based on an assessment of the equipment. Write-offs for equipment are included in cost of revenues. During the years ended December 31, 2021, 2020 and 2019, write-offs for $639, $409 and $327, respectively, were recorded (see Note 7). k. Impairment of long-lived assets: The Company’s long-lived assets are reviewed for impairment in accordance with ASC 360-10, "Property, Plant and Equipment," whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. During the three years ended December 31, 2021, no impairment losses have been identified. l. Other long-term assets: Restricted deposits, long-term lease deposits associated with office rent and vehicles under operating leases, prepaid and vendors down payments are presented in other long-term assets. m. Revenue recognition: Our Products are comprised of two main components: (1) an electric field generator and (2) arrays and related accessories. We retain title to the electric field generator, and the patient is provided replacement arrays and technical support for the device during the term of treatment. The electric field generator and arrays are always supplied and function together and are not sold on a standalone basis. The Company uses the portfolio approach to apply the standard to portfolios of contracts with similar characteristics. To recognize revenue under ASC 606, the Company applies the following five steps: 1. Identify the contract with a patient. A contract with a patient exists when (i) the Company enters into an enforceable contract with a patient that defines each party’s rights regarding delivery of and payment for a Product, (ii) the contract has commercial substance and (iii) the Company determines that collection of substantially all consideration for such Product is probable based on the payer’s intent and ability to pay the promised consideration. The evidence of a contract generally consists of a prescription, a patient service agreement and the verification of the assigned payer for the contract and intention to collect. 2. Identify the performance obligations in the contract. Our contracts include the lease of the device, the supply obligation of disposable arrays and technical support for the term of treatment. To the extent a contract includes multiple promised products and/or services, the Company must apply judgment to determine whether those products and/or services are capable of being distinct in the context of the contract. If these criteria are not met the promised products and/or services are accounted for as a combined performance obligation. In the Company’s case, the device, support, and disposables are provided as one inseparable package of monthly treatment for a single monthly fee. For more information, see Note 2(x). 3. Determine the transaction price. The transaction price is determined based on the consideration to which the Company will be entitled in exchange for providing a Product to the patient. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. The Company has agreements with many payers that define explicit discounts off the gross transaction price. In addition to the explicit discounts negotiated with each payer, the Company expects to receive, in aggregate for a given portfolio, less than the gross revenue net of explicit discounts. ASC 606 requires that the Company recognize this variable consideration as an implicit discount in the billing period. The implicit discount includes both an estimate of claims that will pay at an amount less than billed and an estimate of claims that will not pay within a given time horizon. The implicit discount adjustments to the transaction price are due to concessions, not collectability concerns driven by payer credit risk. 4. Allocate the transaction price to performance obligations in the contract. If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. As discussed above, there is a combined performance obligation under the Company’s contracts and, therefore, the monthly transaction price determined for the performance obligation will be recognized over time ratably over the monthly term of the treatment. 5. Recognize revenue when or as the Company satisfies a performance obligation. The Company satisfies performance obligations over time. Revenue is recognized at the time the related performance obligation is satisfied by transferring a promised service to a patient. The patient consumes the benefits of treatment on a daily basis over the monthly term. As this criterion is met, the revenues will be recognized over the monthly term. For more information, see Note 2(x). Revenues are presented net of indirect taxes. Net revenues in the years ended December 31, 2021, 2020 and 2019 also include amounts recognized pursuant to the Zai Agreement. For additional information, see Note 12. n. Charitable care: The Company provides treatment at no charge to patients who meet certain criteria under its charitable care policy. Because the Company does not pursue collection of amounts determined to qualify as charity, they are not reported as revenue. The Company's costs of care provided under charitable care were $4,204, $3,653 and $2,847 for the years ended December 31, 2021, 2020 and 2019, respectively. These amounts were determined by applying charitable care as a percentage of gross billings to total cost of goods sold. o. Shipping and handling costs: The Company does not separately bill its customers for shipping and handling costs associated with shipping Products to its customers. These direct shipping and handling costs of $2,958, $3,224 and $2,688 for the years ended December 31, 2021, 2020 and 2019, respectively, are included in Sales and Marketing costs. p. Accounting for share-based compensation: The Company accounts for share-based compensation in accordance with ASC 718, "Compensation—Stock Compensation." ASC 718 requires companies to estimate the fair value of share-based compensation awards on the date of grant using an option-pricing model. The value of the award is recognized as an expense over the requisite service periods in the Company’s consolidated statements of operations. The Company's policy is to account for forfeitures as they occur. The Company recognizes compensation costs for the value of awards granted using the accelerated method over the requisite service period of the award, which is generally the restricted share unit vesting term of three years and option vesting term of four years, respectively. The Company applies the Black-Scholes model as it believes it is the most appropriate fair value method for all equity awards and for the Employee Share Purchase Plan (the "ESPP"). For market condition awards, the Company also applies the Monte-Carlo simulation model. The Black-Scholes model requires a number of assumptions, of which the most significant are the share price, expected volatility and the expected award term. Beginning with the first quarter of 2021, the computation of expected volatility is based on a combination of actual historical share price volatility of comparable publicly-traded companies and the historical volatility the Company's shares. Prior to the first quarter of 2021, due to the lack of sufficient historical information for the Company, the computation was based on actual historical volatility of comparable publicly-traded companies. Beginning with the first quarter of 2021, the expected term of options granted is calculated using the Company's historical and future exercise behavior. Prior to the first quarter of 2021, it was calculated using the average between the vesting period and the contractual term to the expected term of the options in effect at the time of grant. The Company has historically not paid dividends and has no foreseeable plans to pay dividends and, therefore, uses an expected dividend yield of zero in the option pricing model. The risk-free interest rate is based on the yield of U.S. treasury bonds with equivalent terms. q. Fair value of financial instruments: The carrying amounts of cash and cash equivalents, short-term investments, restricted cash, receivables and prepaid expenses, trade receivables, trade payables and other accounts payable and accrued expenses approximate their fair value due to the short-term maturity of such instruments. The Company accounts for certain assets and liabilities at fair value under ASC 820, "Fair Value Measurements and Disclosures." Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. The Company categorizes each of its fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. The three levels of inputs that may be used to measure fair value are as follows: Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets; Level 2 - Includes other inputs that are directly or indirectly observable in the marketplace, other than quoted prices included in Level 1, such as quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets with insufficient volume or infrequent transactions, or other inputs that are observable (model-derived valuations in which significant inputs are observable), or can be derived principally from or corroborated by observable market data; and Level 3 - Unobservable inputs which are supported by little or no market activity. The availability of observable inputs can vary from instrument to instrument and is affected by a wide variety of factors, including, for example, the type of instrument, the liquidity of markets and other characteristics particular to the transaction. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment and the instrument is categorized as Level 3. r. Basic and diluted net loss per share: Basic net income (loss) per share is computed based on the weighted average number of ordinary shares outstanding during each period. Diluted net income per share is computed based on the weighted average number of ordinary shares outstanding during the period, plus potential dilutive shares considered outstanding during the period, in accordance with ASC 260-10, as determined under the treasury stock method. s. Income taxes: The Company accounts for income taxes in accordance with ASC 740-10, "Income Taxes." ASC 740-10 prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, to reduce deferred tax assets to their estimated realizable value, if needed. The Company established reserves for uncertain tax positions based on the evaluation of whether or not the Company’s uncertain tax position is "more likely than not" to be sustained upon examination. The Company records interest and penalties pertaining to its uncertain tax positions in the financial statements as income tax expense. t. Concentration of risks: Our cash, cash equivalents, short-term investments and trade receivables are potentially subject to a concentration of risk. Cash, cash equivalents and short-term investments are invested at top tier financial institutions globally. As such, these investments may be in excess of insured limitations or not insured in certain jurisdictions. Generally, these investments may be redeemed upon demand and therefore, bear minimal risk. Our trade receivables are due from numerous governments and federal and state agencies that are paid from their respective budgets, and from hundreds of health insurance companies. The Company does not believe that there are significant default risks associated with these governments, agencies and health insurance companies based upon the Company's the historical experience with them. The Company has no off-balance sheet concentrations of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements. u. Retirement, pension and severance plans: The Company has a 401(k) retirement savings plan for its U.S. employees. Each eligible employee may elect to contribute a portion of the employee’s compensation to the plan. Company contributions to the plan are at the sole discretion of the Company's Board of Directors. Currently, the Company provides a matching contribution of 50% of the employee's contributions, up to a maximum of three percent (3%) of the employee's annual salary. The Company began making matching contributions as of January 1, 2019. For the years ended December 31, 2021, 2020 and 2019, the Company had made matching contributions in the amount of $1,967 and $1,589 and $978, respectively, pursuant to the plan. The Company sponsors a defined benefit plan (the "Swiss Plan") for all its employees in Switzerland for retirement benefits, as well as benefits on death or long-term disability, whereby the employee and the Company contribute a portion of the employee's compensation to the plan. The Swiss Plan is part of a collective pension foundation “Asga Pensionskasse”. Asga is an autonomous pension foundation, meaning that the underlying investment risk and the all biometrical risks (disability, death, longevity) are born by the pension foundation itself. Notwithstanding, the Company and its employees bear the risk of having to pay recovery contributions in a financial distress situation. The Company accounts for this risk in accordance with ASC 715, "Compensation – Retirement Benefits" (see Note 9). The pension expense for the years ended December 31, 2021, 2020 and 2019 was $1,494, $1,588 and $984, respectively. Israeli law generally requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. The Company contributes to employee pension plans to fund its severance liabilities. According to Section 14 of Israel Severance Pay Law, the Company makes deposits on behalf of its employees with respect to the Company’s severance liability and therefore no obligation is provided for in the financial statements. Severance pay liabilities with respect to employees who are not subject to Section 14, are provided for in the financial statements based upon the number of years of service and the latest monthly salary and the related deposits are recorded as an asset based on the cash surrender value. Contributions pursuant to these obligations for the years ended December 31, 2021, 2020 and 2019 amounted to $1,466, $1,130 and $784, respectively. v. Contingent liabilities: The Company accounts for its contingent liabilities in accordance with ASC 450, "Contingencies." A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. w. Other comprehensive income (loss): The Company accounts for comprehensive income (loss) in accordance with ASC 220, "Comprehensive Income." ASC 220 establishes standards for the reporting and display of comprehensive income (loss) and its components. Comprehensive income (loss) generally represents all changes in shareholders' equity during the period except those resulting from investments by, or distributions to, shareholders. The accumulated other comprehensive income (loss), net of taxes, relates to a pension liability and foreign currency translation adjustments. x. Leases: 1. Lessee accounting: On January 1, 2019, the Company adopted ASU No. 2016-02, Leases (ASC 842). The Company determines if an arrangement is a lease and the classification of that lease at inception based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of the asset. The Company elected to not recognize a lease liability or right-of-use ("ROU") asset for leases with a term of twelve months or less. The Company also elected the practical expedient to not separate lease and non-lease components for its leases. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make minimum lease payments arising from the lease. ROU assets are initially measured at amounts, which represents the discounted present value of the lease payments over the lease, plus any initial direct costs incurred. The ROU assets are reviewed for impairment. The lease liability is initially measured at lease commencement date based on the discounted present value of minimum lease payments over the lease term. The implicit rate within the operating leases are generally not determinable; therefore, the Company uses the Incremental Borrowing Rate ("IBR") based on the information available at commencement date in determining the present value of lease payments. The Company’s IBR is estimated to approximate the interest rate on similar terms and payments and in economic environments where the leased asset is located. Certain leases include options to extend or terminate the lease. An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate is considered unless it is reasonably certain that the Company will not exercise the option. 2. Lessor accounting - Operating leases: ASC 842 provides lessors with an optional practical expedient, by class of underlying asset, not to separate non-lease components from the associated lease component and, instead, to account for those components as a single component if the non-lease components otherwise would be accounted for under the new revenue guidance (ASC 606) and both of the following criteria are met: a. The timing and pattern of transfer of the lease component and the non-lease component(s) are the same; and b. The lease component would be classified as an operating lease if it were accounted for separately. The Company's product supply agreements include the right to use the device (lease component), the supply obligation of disposable arrays and technical support for the term of treatment (non-lease component). If the lease component is the predominant component, the Company accounts for all revenues under such lease as a single component in accordance with the new lease accounting standard. Conversely, if the non-lease component is the predominant component, all revenues under such lease are accounted for in accordance with the revenue recognition accounting standard. The Company's operating leases qualify for the single component accounting, and the non-lease component in each of the Company's leases is predominant. Therefore, The Company accounts for all revenues from its operating leases in accordance with the revenue recognition accounting standard. y. Convertible note: Prior to January 1, 2021, the Company accounted for its convertible senior notes in accordance with ASC 470-20 "Debt with Conversion and Other Options". Pursuant to ASC Subtopic 470-20, issuers of certain convertible debt instruments, such as the convertible senior notes, that have a net settlement feature and may be settled wholly or partially in cash upon conversion are required to separately account for the liability (debt) and equity (conversion option) components of the instrument. The Company allocated the proceeds from issuance between the liability component and the embedded conversion option, or equity component. The liability component at issuance is recognized at fair value, based on the fair value of a similar instrument of similar credit rating and maturity that does not have a conversion feature. The equity component is based on the excess of the principal amount of the convertible senior notes over the fair value of the liability component and is recorded in additional paid-in capital. The equity component, net of issuance costs is presented within additional paid-in-capital and is not remeasured as long as it continues to meet the conditions for equity classification. The Company allocated the total issuance costs incurred to the liability and equity components of the convertible senior notes based on the same proportions as the proceeds from the notes. Commencing January 1, 2021, the Company early adopted ASU 2020-06, see note 2(z). z. Recently adopted accounting pronouncements: In August 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (ASU 2020-06), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. Among other changes, ASU 2020-06 removes from GAAP the liability and equity separation model for convertible instruments with a cash conversion feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for such debt. Similarly, the embedded conversion feature will no longer be amortized into income as interest expense over the life of the instrument. Instead, entities will account for a convertible debt instrument wholly as debt unless (1) a convertible instrument contains features that require bifurcation as a derivative under Accounting Standards Codification ("ASC Topic 815"), Derivatives and Hedging, or (2) a convertible debt instrument was issued at a substantial premium. Additionally, ASU 2020-06 requires the application of the if-converted method to calculate the impact of convertible instruments on diluted earnings per share (EPS), which is consistent with the Company’s accounting treatment under the current standard. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted for fiscal years beginning after December 15, 2020, and can be adopted on either a fully retrospective or modified retrospective basis. The Company early adopted ASU 2020-06, effective January 1, 2021 on a modified retrospective basis. The impact of the Company’s adoption of ASU 2020-06 on the balance sheet as of January 1, 2021 was an increase in long term debt, net of $128,972, a decrease in additional paid-in capital of $132,474, and a decrease in accumulated deficit of $3,502. Interest expense recognized in future periods will be reduced as a result of accounting for the convertible debt instrument as a single liability measured at its amortized cost. For additional information see Note 10 of these audited consolidated financial statements. In December 2019, the FASB issued Accounting Standard Update No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12), which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects of the current guidance. ASU 2019-12 is effective for the Company as of January 1, 2021 and the adoption of this standard did not have a material impact on the Company's consolidated financial statements. |
Cash and Cash equivalents and S
Cash and Cash equivalents and Short-term investments | 12 Months Ended |
Dec. 31, 2021 | |
Cash, Cash Equivalents, and Short-term Investments [Abstract] | |
Cash and Cash equivalents and Short-term investments | Cash and Cash equivalents and Short-term investments a. Cash and cash equivalents: Cash equivalents include items almost as liquid as cash, such as certificates of deposit and term deposits with maturity periods of three months or less when purchased. The Company’s cash and cash equivalents were composed of: December 31, 2021 2020 Cash $ 3,139 $ 20,339 Money market funds 64,668 214,335 Certificate of deposits, notes and term deposits 140,995 — Total cash and cash equivalents $ 208,802 $ 234,674 b. Short-term investments The following table sets forth the Company’s short-term investments: December 31, 2021 2020 Term deposits $ 424,094 $ — US treasury bills 199,981 607,902 Corporate debt securities 104,823 — Total short-term investments $ 728,898 $ 607,902 The Company invests in marketable U.S. treasury Bills (“T-bills”), term deposits, notes, and corporate debt securities that are classified as held-to-maturity securities and are presented as cash and cash equivalents and short-term investments according their maturity periods. The Company measures its cash equivalents and short-term investments at fair value and classifies them within Level 1 or 2. The Company values these investments using quoted market prices or alternative pricing sources and models utilizing market observable inputs. The fair value of the Company's Level 1 financial assets is based on quoted market prices of the identical underlying security. The fair value of the Company's level 2 financial assets is based on inputs that are directly or indirectly observable in the market, including the readily-available pricing sources for the identical underlying security that may not be actively traded. The estimated fair value of our short-term investments as of December 31, 2021 and 2020 was $728,906 and $607,905, respectively. As of December 31, 2021 and 2020, amounts of $624,083 and $607,905, respectively, were categorized as level 1, and the remaining balance as level 2 in accordance with ASC 820, “Fair Value Measurements and Disclosures.” |
Receivables and prepaid expense
Receivables and prepaid expenses | 12 Months Ended |
Dec. 31, 2021 | |
Receivables And Prepaid Expenses [Abstract] | |
Receivables and prepaid expenses | Receivables and prepaid expenses The following table sets forth the Company’s receivables and prepaid expenses: December 31, 2021 2020 Advances to and receivables from suppliers $ 3,843 $ 3,768 Government authorities 8,421 13,358 Prepaid expenses 4,711 3,963 Others 50 156 $ 17,025 $ 21,245 |
Inventories
Inventories | 12 Months Ended |
Dec. 31, 2021 | |
Inventory Disclosure [Abstract] | |
Inventories | Inventories Inventories are stated at the lower of cost or net realizable value. The weighted average methodology is applied to determine cost. The following table sets forth the Company’s inventories: December 31, 2021 2020 Raw materials $ 1,485 $ 5,175 Work in process 8,274 4,896 Finished goods 14,668 17,351 $ 24,427 $ 27,422 |
Property and equipment, net
Property and equipment, net | 12 Months Ended |
Dec. 31, 2021 | |
Property, Plant and Equipment [Abstract] | |
Property and equipment, net | Property and equipment, net The following table sets forth the Company’s property and equipment, net: December 31, 2021 2020 Cost: Computers and laboratory equipment $ 21,135 $ 18,821 Office furniture 3,044 2,871 Production equipment 2,377 1,628 Land and building $ 11,155 $ — Leasehold improvements 7,076 6,501 Total cost $ 44,787 $ 29,821 Accumulated depreciation and amortization (22,094) (18,426) Depreciated cost $ 22,693 $ 11,395 The Company capitalized software costs according to FASB's ASC 350-40, "Accounting for the Costs of Computer Software Developed or Obtained for Internal Use." Cumulative capitalization as of December 31, 2021 and 2020 was $9,979 and $9,219, respectively. Amortization of capitalized software costs for the years ended December 31, 2021, 2020 and 2019 was $1,084, $1,398 and $1,682, respectively. Depreciation expense was $2,812, $2,635 and $2,080 for the years ended December 31, 2021, 2020 and 2019, respectively. |
Field equipment, net
Field equipment, net | 12 Months Ended |
Dec. 31, 2021 | |
Field Equipment [Abstract] | |
Field equipment, net | Field equipment, net The following table sets forth the Company’s field equipment, net: December 31, 2021 2020 Field equipment $ 33,789 $ 27,876 Accumulated depreciation (20,866) (16,646) Field equipment, net $ 12,923 $ 11,230 Depreciation expense was $6,355, $5,117 and $4,631 for the years ended December 31, 2021, 2020 and 2019, respectively. Write downs of $639, $409 and $327 were identified for the years ended December 31, 2021, 2020 and 2019, respectively. |
Other payables and accrued expe
Other payables and accrued expenses | 12 Months Ended |
Dec. 31, 2021 | |
Payables and Accruals [Abstract] | |
Other payables and accrued expenses | Other payables and accrued expenses The following table sets forth the Company’s other payables and accrued expenses: December 31, 2021 2020 Employees and payroll accruals $ 39,590 $ 30,316 Government authorities 5,797 5,340 Deferred revenues 17,762 17,765 Other 6,853 6,544 $ 70,002 $ 59,965 |
Employee benefit obligations
Employee benefit obligations | 12 Months Ended |
Dec. 31, 2021 | |
Retirement Benefits [Abstract] | |
Employee benefit obligations | Employee benefit obligationsThe Company's liability in respect of the Swiss Plan (see Note 2(u)) is the projected benefit obligation calculated using the projected unit credit method. The projected benefit obligation as of December 31, 2021 represents the actuarial present value of the estimated future payments required to settle the obligation that is attributable to employee service rendered before that date. Swiss Plan assets are recorded at fair value. Pension expense is presented in the payroll expenses in the various functions in which the employees are engaged. Actuarial gains and losses arising from differences between the actual and the expected return on the Swiss Plan assets are recognized in accumulated other comprehensive income (loss) and amortized over the requisite service period. The Swiss Plan is part of a collective pension foundation of pooled investments managed by a top tier insurance company. The Company and the employees pay retirement contributions, which are defined as a percentage of the employees’ covered salaries.The basis for the determination of the interest on employee’s savings account is the return on plan assets, considering legal minimum requirements. The targeted allocation for these funds is as follows: Asset Allocation by Category as of December 31, 2021: Asset allocation (%) Asset Category: Debt Securities 30% Real Estate 27% Equity Securities 37% Others 6% Total 100% The following table sets forth the Swiss Plan’s funded status and amounts recognized in the consolidated financial statements for the year ended December 31, 2021 and 2020: December 31, 2021 2020 Change in Benefit Obligation Projected benefit obligation at beginning of year $ 22,753 $ 15,685 Interest cost 48 37 Company service cost 1,915 1,483 Employee contributions 1,167 870 Prior service cost (923) — Benefits paid 2,976 1,612 Actuarial loss 2,039 3,066 Projected benefit obligation at end of year $ 29,975 $ 22,753 Change in Plan Assets Fair value of plan assets at beginning of year $ 18,082 $ 12,356 Actual return on plan assets 1,992 1,938 Employer contributions 1,750 1,306 Employee contributions 1,167 870 Benefits paid 2,976 1,612 Fair value of plan assets at end of year $ 25,967 $ 18,082 Funded Status at End of year Excess of obligation over assets $ 4,008 $ 4,671 Change in Accrued Benefit Liability Accrued benefit liability at beginning of year $ (4,671) $ (3,329) Company contributions made during year 1,750 1,306 Net periodic benefit cost for year (1,310) (1,909) Net decrease (increase) in accumulated other comprehensive loss 223 (739) Accrued benefit liability at end of year $ (4,008) $ (4,671) December 31, 2021 2020 Non-current plan assets $ 25,967 $ 18,083 Non-current liability 29,975 22,754 Accrued benefit liability at end of year $ (4,008) $ (4,671) Projected Benefit Payments Projected year 1 $ 567 $ 1,804 Projected year 2 454 394 Projected year 3 819 400 Projected year 4 765 788 Projected year 5 452 405 Projected years 6-10 13,816 3,445 The fair value of the plan assets is the estimated cash surrender value of the insurance contract at December 31, 2021. The level of inputs used to measure fair value was Level 2. Year ended December 31, 2021 2020 Net Periodic Benefit Cost Service cost $ 1,915 $ 1,483 Interest cost (income) 48 37 Expected return on plan assets (508) (31) Amortization of actuarial (gain) loss 133 120 Amortization of prior service costs (94) (21) Total net periodic benefit cost $ 1,494 $ 1,588 Weighted average assumptions: Discount rate as of December 31 0.20% 0.20 % Expected long-term rate of return on assets 2.50% 0.20 % Rate of compensation increase 1.00% 1.00% Mortality and disability assumptions (*) BVG 2020 GT BVG 2015 GT (*) Mortality data used for actuarial calculation. |
Long-term debt, net
Long-term debt, net | 12 Months Ended |
Dec. 31, 2021 | |
Debt Disclosure [Abstract] | |
Long-term debt, net | Long-term debt, net The following table sets forth the Company’s long-term debt, net: December 31, 2021 2020 0% Convertible Senior Notes (a) $ 562,216 $ 429,905 Credit facility (b) — — $ 562,216 $ 429,905 a. Convertible Notes On November 5, 2020, the Company issued $575,000 aggregate principal amount of 0% Convertible Senior Notes due 2025 (the “Notes”). The net proceeds from the offering were approximately $558,400. The Notes are senior unsecured obligations of the Company. The Notes do not bear regular interest, and the principal amount of the Notes will not accrete. Special interest, if any, payable in accordance with the terms of the Notes will be payable in cash semi-annually in arrears on May 1 and November 1 of each year, beginning on May 1, 2021. The Notes mature on November 1, 2025, unless earlier repurchased, redeemed or converted. The Notes are convertible into cash, the Company’s ordinary shares or a combination of cash and the Company’s ordinary shares at the Company’s election at an initial conversion rate of 5.9439 ordinary shares per $1,000 principal amount of the Notes, which is equivalent to an initial conversion price of approximately $168.24 per ordinary share. In January 2021, the Company irrevocably elected to settle all conversions of Notes by a combination of cash and the Company's ordinary shares and that the cash portion per $1,000 principal amount of Notes for all conversion settlements shall be $1,000. Accordingly, from and after the date of the election, upon conversion of any Notes, holders of Notes will receive, with respect to each $1,000 principal amount of Notes converted, cash in an amount up to $1,000 and the balance of the conversion value, if any, in ordinary shares (the "Conversion Shares"). The Notes are not redeemable prior to November 6, 2023, except in the event of certain tax law changes. The Company may redeem for cash all or any portion of the Notes, at the Company’s option, on or after November 6, 2023 if the last reported sale price of the Company’s ordinary shares has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid special interest, if any, to, but excluding, the redemption date. No sinking fund is provided for the Notes. Prior to the close of business on the business day immediately preceding August 1, 2025, the Notes are convertible at the option of the holders only upon the satisfaction of certain conditions and during certain periods as described below and if the Company exercises its right to redeem the Notes as permitted or required by the Indenture as described below. On or after August 1, 2025 until the close of the business on the business day immediately preceding the maturity date, holders may convert all or any portion of their Notes at the conversion rate at any time irrespective of the foregoing conditions. If holders of at least $3,000 aggregate principal amount of the Notes provide the Company with reasonable evidence that the trading price per $1,000 principal amount of Notes (the “Note Trading Price”) on any trading day would be less than 98% of the product of the last reported sale price of the Ordinary Shares on such trading day and the conversion rate on such trading day (the “Trigger Note Price”), the Company shall follow the process for obtaining the Note Trading Price as provided in the Indenture on a daily basis until the Note Trading Price exceeds the Trigger Notice Price. During this time, if during any five consecutive trading day period (the “Measurement Period”) the Note Trading Price is less than 98% of the Trigger Notice Price, the Company must notify the holders and the trustee of such an event and the holders may convert their Notes into Ordinary Shares at any time during the five business day period immediately after. If the Company intends to (i) issue warrants/rights/options to existing shareholders with an exercise price less than the ten-day trailing last trading price average or (ii) distribute to shareholders assets, securities or rights with a value per share greater than 10% of the last reported trading price, then the Company must give holders of the Notes thirty-five (35) trading days’ notice of such event, at which time a holder may convert their Notes during such 35 trading day period (or until the Company revokes its decision to issue/distribute the securities, whichever comes sooner). In addition, upon the occurrence of a fundamental change (as defined in the indenture), holders may require the Company to repurchase for cash all or any portion of their Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid special interest, if any, to, but excluding, the fundamental change repurchase date. In addition, following certain corporate events that occur prior to the maturity date or if the Company delivers a notice of redemption, the Company will, in certain circumstances, increase the conversion rate for a holder who elects to convert its Notes in connection with such a corporate event or notice of redemption, as the case may be. As of December 31, 2021, the conditions allowing holders of the Notes to convert were not met. The Notes are therefore not convertible as of December 31, 2021 and are classified as long-term liability. The net carrying amount of the liability and equity components of the Convertible Notes (see note 2(z) for additional information) as of December 31, 2021 and 2020 are as follows: December 31, 2021 2020 Liability component, net: Principal amount $ 575,000 $ 575,000 Unamortized discount — (132,797) Unamortized issuance costs (12,784) (12,298) Net carrying amount of liability component (1) $ 562,216 $ 429,905 Equity component, net: Conversion feature $ — $ 136,402 Issuance costs $ — (3,928) Net carrying amount of equity component $ — $ 132,474 (1) An effective interest rate determines the fair value of the Notes, therefore they are categorized as Level 3 in accordance with ASC 820, "Fair Value Measurements and Disclosures." The estimated fair value of the Net carrying amount of liability component of the Notes as of December 31, 2021 and 2020 were $467,469 and $450,437, respectively. Finance expense related to the Notes were as follows: Year ended December 31, 2021 2020 Amortization of debt issuance costs $ 3,339 $ 333 Amortization of debt discount $ — $ 3,605 Total finance expense recognized $ 3,339 $ 3,938 b. Loan and Security Agreement On February 7, 2018, the Company and certain of its subsidiaries entered into a Loan and Security Agreement ("2018 Loan Agreement") with BioPharma Credit PLC pursuant to which such lender made a term loan to the Company in the principal amount of $150,000 (the "2018 Credit Facility"). The term loan, which was drawn in full upon execution of the 2018 Loan Agreement, bore interest at 9.0% per annum, payable quarterly in arrears. On August 18, 2020, the Company terminated the 2018 Credit Facility. The prepayment included $150,000 in principal repayment and $3,000 in prepayment premium, plus accrued and unpaid interest and expenses payable through the payoff date. The un-amortized issuance costs in the amount of $478 that were fully amortized upon the repayment and the prepayment premium were reported in the Company’s finance expenses. |
Other long-term liabilities
Other long-term liabilities | 12 Months Ended |
Dec. 31, 2021 | |
Other Liabilities Disclosure [Abstract] | |
Other long-term liabilities | Other long-term liabilities December 31, 2021 2020 Leasehold improvements financing and other $ 12 $ 40 Unrecognized tax benefits (Note 13(e)) 154 297 $ 166 $ 337 |
Commitments and contingent liab
Commitments and contingent liabilities | 12 Months Ended |
Dec. 31, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and contingent liabilities | Commitments and contingent liabilities a. Operating leases The facilities of the Company are leased under various operating lease agreements for periods ending no later than 2030. The Company also has the option to extend the term of certain facility lease agreements and these are included in the calculation of right-of-use assets. The Company also leases motor vehicles under various operating leases, which expire on various dates, the latest of which is in 2024. Under ASC 842, all leases with durations greater than 12 months, including non-cancelable operating leases, are recognized on the balance sheet. The aggregated present value of lease payments is recorded as a long-term asset titled right-of-use assets. The corresponding lease liabilities are split between other payables and long-term lease liabilities, and as of December 31, 2021, are as follows: December 31, 2021 Future minimum lease payments: 2022 $ 6,925 2023 4,959 2024 3,508 2025 2,083 2026 1,990 Thereafter 2,511 Total future minimum lease payments $ 21,976 Less imputed interest (2,295) Net present value of future minimum lease payments $ 19,681 Current year end Short-term lease liabilities $ 6,684 Long-term lease liabilities 12,997 Net present value of future minimum lease payments $ 19,681 Weighted average of remaining operating lease term (years) 4.47 Weighted average of operating lease discount rate 5.62 % Lease and rental expense for the years ended December 31, 2021, 2020 and 2019 was $7,349, $5,950, and $5,410, respectively. b. Bank guarantee and pledges As of December 31, 2021 and 2020 the Company pledged bank deposits of $2,350 and $1,438, respectively, to cover bank guarantees in respect of its leases of operating facilities and obtained guarantees by the bank for the fulfillment of the Company’s lease commitments of $2,698 and $1,687, respectively. c. Senior secured revolving credit facility On November 6, 2020, the Company entered into a new three-year $150,000 senior secured revolving credit facility with a syndicate of relationship banks. The Company may, subject to certain conditions and limitations, increase the revolving credit commitments outstanding under the revolving credit facility or incur new incremental term loans in aggregate principal amount not to exceed $250.0 million in total. The commitments under the revolving credit facility are guaranteed by certain of the Company's subsidiaries and secured by a first lien on the Company's and certain of the Company's subsidiaries’ assets. Outstanding loans will bear interest per annum at a sliding scale based on the Company's secured leverage ratio from 2.75% to 3.25% above the applicable interbank borrowing reference rate for the currency in which the loan is denominated. Additionally, the facility contains a fee for the unused revolving credit commitments at a sliding scale based on the Company's secured leverage ratio from 0.35% to 0.45%. The facility contains financial covenants requiring maintenance of a minimum fixed charge coverage ratio and specifying a maximum senior secured net leverage ratio, as well as customary events of default which include a change of control. As of December 31, 2021, the Company had no outstanding balance borrowed under the facility. d. Zai License and Collaboration Agreement On September 10, 2018, the Company entered into the Zai Agreement. Under the Zai Agreement, the Company granted Zai exclusive rights to commercialize Optune in the field of oncology in China, Hong Kong, Macau and Taiwan ("Greater China"). The Zai Agreement also established a development partnership for Optune in multiple solid tumor indications. In partial consideration for the license grant to Zai for Greater China, the Company was entitled to a non-refundable, up-front license fee in the amount of $15,000 (the "License Fee"). The Zai Agreement also provides for certain development, regulatory and commercial milestone payments totaling up to $78,000. Furthermore, pursuant to the Zai Agreement, Zai will pay the Company tiered royalties at percentage rates from 10 up to the mid-teens on the net sales of the licensed products in Greater China. Zai is purchasing licensed products for commercial use exclusively from the Company at the Company’s fully burdened manufacturing cost. The Company recognizes revenue pursuant to the License Agreement with Zai in accordance with ASC 606, "Revenue Recognition from Customers." The License Fee is deferred and recognized over related six During the year ended December 31, 2020, the Company triggered an aggregate $10,000 of milestone payments, which, with the License Fee, are deferred and recognized over the remainder of the Zai Performance Period ending in September 2024 on a straight-line basis, resulting in revenue of $6,308 $3,981 and $2,115 for the years ended December 31, 2021, 2020 and 2019, respectively. |
Income taxes
Income taxes | 12 Months Ended |
Dec. 31, 2021 | |
Income Tax Disclosure [Abstract] | |
Income taxes | Income taxes a. Tax provision : Income (loss) before income taxes is as follows: Year ended December 31, 2021 2020 2019 United States (U.S.) $ 82,249 $ (15,283) $ (87,925) Non-U.S. (134,324) 33,385 79,101 Total income (loss) before income taxes $ (52,075) $ 18,102 $ (8,824) The provision (benefit) for income taxes from continuing operations is comprised of: Year ended December 31, 2021 2020 2019 Current: U.S. $ 65 $ (11,898) $ (6,143) Non-U.S. 6,211 10,192 4,405 Total current $ 6,276 $ (1,706) $ (1,738) Deferred: Non-U.S. — — 144 Total deferred — — 144 Total income tax provision $ 6,276 $ (1,706) $ (1,594) b. Theoretical tax The Company's effective tax rate is affected by the tax rates in the various jurisdictions in which the Company operates. For purposes of comparability, the Company used the notional U.S. federal income tax rate of 21% for the 2021, 2020 and 2019 tax years when presenting the Company's reconciliation of the income tax provision. A reconciliation of the provision for income taxes compared with the amounts at the notional federal statutory rate was: Year ended December 31, 2021 2020 2019 Income (loss) before income taxes $ (52,075) $ 18,102 $ (8,824) U.S. statutory income tax rate 21.0 % 21.0 % 21.0 % Notional U.S. federal income taxes at statutory rate $ (10,936) $ 3,801 $ (1,853) Foreign taxes rate differential 14,651 4,024 (4,216) Share based compensation (12,669) (6,190) (26,528) Change in valuation allowance 11,643 6,821 244,344 Return to provision true-ups 2,416 654 (5,204) Research and Development Credits (2,216) (5,243) (2,333) State income taxes 1,572 607 (16,679) Withholding Taxes 273 2,366 384 Non-deductible expenses (147) 260 357 Unamortized intangible assets — — (189,410) 2020 Cares Act — (8,694) — Other 1,689 (112) (456) Income tax $ 6,276 $ (1,706) $ (1,594) Effective tax rate (12.1) % (9.4) % 18.1 % c. Deferred income tax Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets and liabilities are as follows: December 31, 2021 2020 Deferred tax assets: Unamortized intangible assets $ 138,978 $ 157,930 Impact of revenue recognition $ 112,251 $ 131,395 Net operating loss carryforwards $ 77,664 $ 40,314 Share based compensation $ 25,644 $ 17,595 Research and development $ 12,146 $ 9,186 Interest limitations $ 7,948 $ 6,975 Lease liability $ 4,836 $ 1,006 Other temporary differences $ 3,032 $ 2,822 Total gross deferred tax assets $ 382,499 $ 367,223 Less: valuation allowance (375,717) (364,082) Total deferred tax assets 6,782 3,141 Deferred tax liabilities: Right of use assets 4,559 936 Fixed assets 2,214 2,185 Other liabilities 9 20 Total gross deferred tax liabilities $ 6,782 $ 3,141 Net deferred taxes assets (liability) $ — $ — d. Carryforward loss: The Company had $790,668 of gross non-U.S net operating carryforwards (NOLs) as of December 31, 2021 of which $1,968 carry forward indefinitely. The remainder expires from 2026 through 2038. Approximately $783,347 of these NOLs are attributable to Novocure Switzerland with $405,553 available at the Federal level and $377,794 available at the cantonal level. In the U.S., the Company had $98,120 of U.S. federal NOLs and $124,146 of U.S. state NOLs. The U.S. federal NOLs carry forward indefinitely. Also, approximately $24,263 in U.S. state NOLs carry forward indefinitely, with the remainder expiring from 2023 through 2040. e. Uncertain tax benefits: A reconciliation of the beginning and ending balances of uncertain tax benefits is as follows: December 31, 2021 2020 2019 Balance at beginning of the year $ 297 $ 116 $ 103 Additions (reductions) for taxes positions related to prior years (143) 181 13 Balance at the end of the year $ 154 $ 297 $ 116 The Company recognizes interest and penalties related to unrecognized tax benefits in tax expense. During the years ended December 31, 2021, 2020 and 2019, the Company accrued $5, $21 and $13, respectively, for interest and penalties expenses related to uncertain tax positions. The Company files income tax returns in the U.S. and various state and foreign jurisdictions. Currently, the Company is under examination by the tax authorities in Israel for the tax years 2017, 2018 and 2019 and is not under examination by any other tax authority. Additional tax years within the period 2015 to 2020 remain subject to examination by the U.S. Internal Revenue Service. Furthermore, tax years 2015 to 2020 remain subject to examination in other U.S. state and municipal jurisdictions, as well as foreign jurisdictions. |
Share capital
Share capital | 12 Months Ended |
Dec. 31, 2021 | |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract] | |
Share capital | Share capital Share capital is composed as follows: Issued and outstanding Number of shares December 31, 2021 2020 Ordinary shares no par value 103,971,263 102,334,276 Equity incentive plans: Stock option plan Until the IPO in October 2015, the Company maintained and granted option awards under the 2003 Share Option Plan (the "2003 Plan") and the 2013 Equity Incentive Share Option Plan (the "2013 Plan") for the Company’s officers, directors, employees and advisors. The 2003 Plan and the 2013 Plan terminated as of the IPO as to future awards, but they continue to govern option awards previously granted thereunder. In September 2015, the Company adopted the 2015 Omnibus Incentive Plan (the "2015 Plan"). The Company’s shareholders approved the 2015 Plan in September 2015. Under the 2015 Plan, the Company can issue various types of equity compensation awards such as restricted shares, performance shares, restricted stock units ("RSUs"), performance share units ("PSUs"), long-term cash award and other share-based awards. Options granted under the 2015 Plan generally have a vesting period of four years and expire ten years after the date of grant. RSUs granted under the 2015 Plan vest in equal installments over three years. PSUs granted under the 2015 Plan generally vest have a vesting period between three On December 31, 2021, in accordance with the terms of the 2015 Plan, the number of shares available for issuance under the 2015 Plan automatically increased by 4% of the Company’s outstanding ordinary shares as of December 31, 2021. As a result, the number of shares available for issuance under the 2015 Plan increased from 35,107,569 shares to 39,264,853 shares. As of December 31, 2021,18,581,409 ordinary shares are available for grant under the 2015 Plan. Employee Stock Purchase Plan In September 2015, the Company adopted an ESPP to encourage and enable eligible employees to acquire ownership of the Company’s ordinary shares purchased through accumulated payroll deductions on an after-tax basis. The ESPP is intended to be an "employee stock purchase plan" within the meaning of Section 423 of the Code and the provisions of the ESPP will be construed in a manner consistent with the requirements of such section. The Company began its offerings under the ESPP on August 1, 2016. The Company issued 51,370 ordinary shares for the plan period from January 1, 2021 through December 31, 2021. The terms of the ESPP provide that on December 31 of each year, the number of shares available for purchase by eligible employees who participate in the ESPP automatically increases by 1% of the Company’s outstanding ordinary shares outstanding, unless the Company determines that such an increase is not necessary. The Company determined that an such increase was not necessary and no such increase took place. As of December 31, 2021, 4,954,997 ordinary shares are available for offering under the ESPP. The fair value of share-based awards was estimated using the Black-Scholes model for all equity grants and for market condition awards. The Company also applied the Monte-Carlo simulation model, with the following underlying assumptions: Year ended December 31, 2021 2020 2019 Stock Option Plans Expected term (years) 5.50-6.00 5.50-6.00 5.50-6.00 Expected volatility 60%-63% 54%-56% 55%-61% Risk-free interest rate 0.78%-1.27% 0.30%-0.86% 1.73%-2.40% Dividend yield 0.00 % 0.00 % 0.00 % ESPP Expected term (years) 0.50 0.50 0.50 Expected volatility 54%-81% 47%-66% 44%-62% Risk-free interest rate 0.05%-0.09% 0.17%-1.57% 2.10%-2.51% Dividend yield 0.00 % 0.00 % 0.00 % A summary of the status of the Company’s options to purchase ordinary shares as of December 31, 2021 and changes during the year ended on that date is presented below: Year ended December 31, 2021 Number of options Weighted average exercise price Aggregate intrinsic value Outstanding at beginning of year 9,220,326 $ 26.21 Granted 466,360 149.96 Exercised (1,016,369) 20.81 Forfeited and cancelled (120,995) 62.77 Outstanding at end of year 8,549,322 $ 33.09 $ 394,997 Exercisable options 5,145,149 $ 19.76 $ 285,295 A summary of the status of the Company’s RSUs and PSUs as of December 31, 2021 and changes during the year ended on that date is presented below: Year ended December 31, 2021 Number of Weighted average grant date fair value price Aggregate intrinsic value Unvested at beginning of year 4,466,151 $ 54.06 Granted 632,275 138.37 Vested (569,248) 52.63 Forfeited and cancelled (70,071) 94.41 Unvested at end of year (1) 4,459,107 $ 65.56 $ 334,790 (1) Includes PSUs that have a mix of service, market and other milestone performance vesting conditions which are vested upon achievements of market and performance conditions which are not probable, as of December 31, 2021, in accordance with ASC 718 as follows: December 31, 2021 Number of Fair value at grant date per PSU Total fair value at grant date 2,703,852 $ 48.16 $ 130,218 108,113 69.37 7,500 17,712 84.68 1,500 10,532 94.94 1,000 189,626 $ 114.26 $ 21,667 3,029,835 $ 161,885 These PSUs will be expensed over the performance period when the vesting conditions become probable in accordance with ASC 718. The total equity-based compensation expense related to all of the Company’s equity incentive plans recognized for the years ended December 31, 2021, 2020 and 2019, was comprised as follows: Year ended December 31, 2021 2020 2019 Cost of revenues $ 3,471 $ 2,221 $ 2,231 Research, development and clinical studies 27,597 18,125 7,570 Sales and marketing 22,673 17,672 11,897 General and administrative 41,159 37,703 30,718 Total share-based compensation expense $ 94,900 $ 75,721 $ 52,416 As of December 31, 2021, unamortized share-based compensation costs amounted to $96,379 and are expected to be recognized over a weighted average period of approximately 2.63 years. The weighted average grant date exercise price of the Company’s options granted during the years ended December 31, 2021, 2020 and 2019 were $149.96, $71.87 and $50.45 per share, respectively. The weighted average grant date fair values of the Company’s options forfeited and cancelled during the years ended December 31, 2021, 2020 and 2019 were $62.77, $22.98 and $22.11, respectively. The aggregate intrinsic values for the options exercised during the years ended December 31, 2021, 2020 and 2019 were $143,695, $156,910 and $266,626, respectively. The aggregate intrinsic value is calculated as the difference between the per share exercise price and the deemed fair value of the Company’s ordinary shares for each share subject to an option multiplied by the number of shares subject to options at the date of exercise. The Company deemed the fair value of the Company’s ordinary shares to be $75.08, $173.04 and $84.27 per share as of December 31, 2021, 2020, and 2019, respectively. Options outstanding as of December 31, 2021 are as follows: Exercise price Number of options outstanding Weighted average remaining contractual term Number of options exercisable Weighted average remaining contractual term $ (years) (years) 0.00 - 10.00 1,116,075 4.48 1,116,075 4.48 10.01 - 20.00 2,668,814 4.94 1,787,295 4.74 20.01 - 30.00 1,886,852 5.53 1,461,424 5.35 30.01 - 40.00 331,417 6.56 272,217 6.54 40.01 - 60.00 1,200,783 7.29 274,740 7.21 60.01 - 100.00 871,555 8.18 227,804 8.13 100.01 - 160.00 462,606 9.25 5,594 8.85 160.01 - 220.00 11,220 9.42 — 0.00 8,549,322 5.97 5,145,149 5.24 |
Financial expenses, net
Financial expenses, net | 12 Months Ended |
Dec. 31, 2021 | |
Interest and Debt Expense [Abstract] | |
Financial expenses, net | Financial expenses, net The following table sets forth the Company’s total financial expenses, net: Year ended December 31, 2021 2020 2019 Financial expenses: Interest expense $ (101) $ (13,068) $ (13,718) Revolving credit facility fee (588) (79) — Amortization of discount and issuance costs (3,339) (4,514) (156) Foreign currency transaction losses (4,032) — (431) Others (779) (389) (338) $ (8,839) $ (18,050) $ (14,643) Financial income: Amortization of investments premium $ 306 $ 1,316 $ 2,331 Foreign currency transaction gains — 2,648 — Interest income 791 1,787 4,402 $ 1,097 $ 5,751 $ 6,733 Total financial expenses, net $ (7,742) $ (12,299) $ (7,910) |
Basic and diluted net income (l
Basic and diluted net income (loss) per share | 12 Months Ended |
Dec. 31, 2021 | |
Earnings Per Share [Abstract] | |
Basic and diluted net income (loss) per share | Basic and diluted net income (loss) per shareBasic net income (loss) per share is computed based on the weighted average number of ordinary shares outstanding during each period. Diluted net income per share is computed based on the weighted average number of ordinary shares outstanding during the period, plus potential dilutive shares (deriving from options, RSUs, PSUs, convertible notes and the ESPP) considered outstanding during the period, in accordance with ASC 260-10, as determined under the treasury stock method. The following table sets forth the computation of the Company’s basic and diluted net loss per ordinary share: Year ended December 31, 2021 2020 2019 Net income (loss) attributable to ordinary shares as reported $ (58,351) $ 19,808 $ (7,230) Net income (loss) used in computing basic net income (loss) per share $ (58,351) $ 19,808 $ (7,230) Adjustment needed in calculating diluted net income (loss) per share — — — Net income (loss) used in computing diluted net income (loss) per share $ (58,351) $ 19,808 $ (7,230) Weighted average number of ordinary shares used in computing basic net income (loss) per share 103,433,274 100,930,866 97,237,549 Potentially dilutive shares that were excluded from the computation of basic net income (loss) per share: Options — 6,967,554 — Restricted share units — 945,612 — ESPP — 33,616 — Weighted average number of ordinary shares used in computing diluted net income (loss) per share 103,433,274 108,877,648 97,237,549 Weighted anti-dilutive shares outstanding which were not included in the diluted calculation 8,524,922 1,307,762 10,230,982 Basic net income (loss) per ordinary share $ (0.56) $ 0.20 $ (0.07) Diluted net income (loss) per ordinary share $ (0.56) $ 0.18 $ (0.07) |
Subcontractor
Subcontractor | 12 Months Ended |
Dec. 31, 2021 | |
Subcontractor [Abstract] | |
Subcontractor | SubcontractorIn certain markets and for certain key components, the Company is currently dependent upon sole source suppliers used in its devices. The Company’s management believes that in most cases other suppliers could provide similar components at comparable terms. A change of suppliers which requires FDA or other regulatory approval, however, could cause a material delay in manufacturing and a possible loss of sales, which could adversely affect the Company’s operating results and financial position. |
Supplemental information
Supplemental information | 12 Months Ended |
Dec. 31, 2021 | |
Geographic Areas, Long-Lived Assets [Abstract] | |
Supplemental information | Supplemental information The following table presents long-lived assets by location: December 31, 2021 2020 United States $ 23,263 $ 11,868 Israel 5,297 4,370 Switzerland 4,085 2,849 Germany 1,020 1,075 Japan 799 1,230 Others 1,152 1,233 Total long-lived assets $ 35,616 $ 22,625 The Company’s net revenues by geographic region, based on the patient’s location are summarized as follows: Year ended December 31, 2021 2020 2019 United States $ 353,110 $ 340,782 $ 232,805 EMEA: Germany 93,939 93,264 86,564 Other EMEA 30,577 18,654 8,782 Japan 34,640 29,076 17,912 Greater China (1) 22,765 12,590 5,255 Total net revenues $ 535,031 $ 494,366 $ 351,318 (1) For additional information, see Note 12. |
Selected quarterly financial in
Selected quarterly financial information (Unaudited) | 12 Months Ended |
Dec. 31, 2021 | |
Selected Quarterly Financial Information [Abstract] | |
Selected quarterly financial information (Unaudited) | Selected quarterly financial information (Unaudited) The following table sets forth selected financial information for the Company: 2021 Three months ended December 31 September 30 June 30 March 31 Net revenues $ 133,213 $ 133,606 $ 133,517 $ 134,695 Gross profit 103,526 103,400 104,918 108,310 Operating income (loss) (23,398) (8,552) (12,295) (88) Net income (loss) (26,458) (13,124) (14,641) (4,128) Basic net income (loss) per ordinary share $ (0.25) $ (0.13) $ (0.14) $ (0.04) Weighted average number of ordinary shares used in computing basic net income (loss) per share 103,884,288 103,731,147 103,484,866 102,633,545 Diluted net income (loss) per ordinary share $ (0.25) $ (0.13) $ (0.14) $ (0.04) Weighted average number of ordinary shares used in computing diluted net income (loss) per share 103,884,288 103,731,147 103,484,866 102,633,545 2020 Three months ended December 31 September 30 June 30 March 31 Net revenues $ 143,953 $ 132,660 $ 115,925 $ 101,828 Gross profit 115,817 104,265 90,451 77,332 Operating income (loss) 12,092 15,022 6,668 (3,381) Net income (loss) 4,917 9,284 1,655 3,952 Basic net income (loss) per ordinary share $ 0.05 $ 0.09 $ 0.02 $ 0.04 Weighted average number of ordinary shares used in computing basic net income (loss) per share 101,945,085 101,234,306 100,718,893 99,877,567 Diluted net income (loss) per ordinary share $ 0.04 $ 0.09 $ 0.02 $ 0.04 Weighted average number of ordinary shares used in computing diluted net income (loss) per share 110,604,714 108,643,814 107,647,802 108,100,623 2019 Three months ended December 31 September 30 June 30 March 31 Net revenues $ 99,234 $ 92,062 $ 86,713 $ 73,309 Gross profit 74,448 69,162 65,607 53,495 Operating income (loss) 153 3,855 1,196 (6,118) Net income (loss) 4,260 1,930 (1,270) (12,150) Basic net income (loss) per ordinary share $ 0.04 $ 0.02 $ (0.01) $ (0.13) Weighted average number of ordinary shares used in computing basic net income (loss) per share 99,226,445 98,485,519 96,356,317 94,811,282 Diluted net income (loss) per ordinary share $ 0.04 $ 0.02 $ (0.01) $ (0.13) Weighted average number of ordinary shares used in computing diluted net income (loss) per share 107,911,519 107,604,578 96,356,317 94,811,282 |
Basis of presentation and sig_2
Basis of presentation and significant accounting policies (Policies) | 12 Months Ended |
Dec. 31, 2021 | |
Accounting Policies [Abstract] | |
Use of estimates | Use of estimates:The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions, including those related to contingencies, deferred taxes, tax liabilities, useful-life of field equipment, right-of-use assets and lease liabilities, convertible notes, pension liabilities, revenue recognition, accrued expenses and share-based compensation costs. The Company’s management believes that the estimates, judgment and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of net revenue and expenses during the reporting period. Actual results could differ from those estimates. |
Financial statements in U.S. dollars | Financial statements in U.S. dollars: The accompanying financial statements have been prepared in U.S. dollars in thousands, except for share and per-share data. The Company finances its operations in U.S. dollars and a substantial portion of its costs and revenues from its primary markets is incurred in U.S. dollars. As such, the Company’s management believes that the U.S. dollar is the currency of the primary economic environment in which NovoCure Limited and certain subsidiaries operate. The Company’s reporting currency is U.S. dollars. Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts maintained in currencies other than the U.S. dollar are re-measured into dollars in accordance with Accounting Standards Codification (ASC) No. 830-10, "Foreign Currency Matters." All transaction gains and losses of the re-measurement of monetary balance sheet items are reflected in the consolidated statements of operations as financial income or expenses, as applicable. For a subsidiary whose functional currency has been determined to be its local currency, assets and liabilities are translated at year-end exchange rates and statement of operations items are translated at average exchange rates prevailing during the year. Such translation adjustments are recorded as a separate component of accumulated other comprehensive income (loss) in shareholders' equity. |
Principles of consolidation | Principles of consolidation:The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Intercompany transactions and balances, including unrealized profits from intercompany sales, have been eliminated upon consolidation. |
Cash equivalents | Cash equivalents:Cash equivalents are short-term, highly liquid investments that are readily convertible into cash with a maturity of three months or less at the date acquired. |
Short-term investments | Short-term investments: The Company accounts for investments in debt securities in accordance with ASC 320, "Investments—Debt and Equity Securities." Management determines the appropriate classification of its investments in marketable debt securities at the time of purchase and reevaluates such determinations at each balance sheet date. For the years ended December 31, 2021 and 2020, all securities are classified as held-to-maturity since the Company has the intent and ability to hold the securities to maturity and, accordingly, debt securities are stated at amortized cost. The amortized cost of held-to-maturity securities is adjusted for amortization of premiums and accretion of discounts to maturity and any credit losses. Such amortization and interest are included in the consolidated statement of operations as financial income or expenses, as appropriate. For the three years ended December 31, 2021, no credit losses have been identified. |
Restricted cash | Restricted cash The Company has restricted cash used as security for the use of Company credit cards and cash management, presented in short-term assets. Additionally, the Company has pledged bank deposits to cover bank guarantees related to facility rental agreements, fleet lease agreements and customs payments presented in other long-term assets (see Note 12). |
Trade receivables | Trade receivables:The Company’s trade receivables balance contains billed and unbilled commercial activities. The Company records an allowance for credit losses, if identified. The Company periodically reviews its customers’ credit risk and payment history. To date, the Company has not experienced any material credit losses related to counter-party risk. |
Inventories | Inventories: Inventories are stated at the lower of cost or net realizable value. Cost is determined using the weighted average method. The Company regularly evaluates its ability to realize the value of inventory. If the inventories are deemed damaged, if actual demand for the Company’s devices deteriorates, or if market conditions are less favorable than those projected, inventory write-offs may be required. Inventory write-offs of $1,045, $616 and $310, respectively, were recorded for the years ended December 31, 2021, 2020 and 2019. |
Property and field equipment | Property and equipment: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following rates: % Computers and laboratory equipment 15 - 33 Office furniture 6 - 33 Production equipment 20 Leasehold improvements Over the shorter of the term of the lease or its useful life Land and assets held within construction in progress are not depreciated. Construction in progress is related to the construction or development of property and equipment that is not yet ready for its intended use. j. Field equipment: Field equipment is stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful life of the field equipment, which was determined to be 18 to 36 months. Field equipment is equipment being utilized under service agreements, and accounted for in accordance with ASC 842 on |
Impairment of long-lived assets | Impairment of long-lived assets:The Company’s long-lived assets are reviewed for impairment in accordance with ASC 360-10, "Property, Plant and Equipment," whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. During the three years ended December 31, 2021, no impairment losses have been identified. |
Other long-term assets | Other long-term assets:Restricted deposits, long-term lease deposits associated with office rent and vehicles under operating leases, prepaid and vendors down payments are presented in other long-term assets. |
Revenue recognition | Revenue recognition: Our Products are comprised of two main components: (1) an electric field generator and (2) arrays and related accessories. We retain title to the electric field generator, and the patient is provided replacement arrays and technical support for the device during the term of treatment. The electric field generator and arrays are always supplied and function together and are not sold on a standalone basis. The Company uses the portfolio approach to apply the standard to portfolios of contracts with similar characteristics. To recognize revenue under ASC 606, the Company applies the following five steps: 1. Identify the contract with a patient. A contract with a patient exists when (i) the Company enters into an enforceable contract with a patient that defines each party’s rights regarding delivery of and payment for a Product, (ii) the contract has commercial substance and (iii) the Company determines that collection of substantially all consideration for such Product is probable based on the payer’s intent and ability to pay the promised consideration. The evidence of a contract generally consists of a prescription, a patient service agreement and the verification of the assigned payer for the contract and intention to collect. 2. Identify the performance obligations in the contract. Our contracts include the lease of the device, the supply obligation of disposable arrays and technical support for the term of treatment. To the extent a contract includes multiple promised products and/or services, the Company must apply judgment to determine whether those products and/or services are capable of being distinct in the context of the contract. If these criteria are not met the promised products and/or services are accounted for as a combined performance obligation. In the Company’s case, the device, support, and disposables are provided as one inseparable package of monthly treatment for a single monthly fee. For more information, see Note 2(x). 3. Determine the transaction price. The transaction price is determined based on the consideration to which the Company will be entitled in exchange for providing a Product to the patient. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. The Company has agreements with many payers that define explicit discounts off the gross transaction price. In addition to the explicit discounts negotiated with each payer, the Company expects to receive, in aggregate for a given portfolio, less than the gross revenue net of explicit discounts. ASC 606 requires that the Company recognize this variable consideration as an implicit discount in the billing period. The implicit discount includes both an estimate of claims that will pay at an amount less than billed and an estimate of claims that will not pay within a given time horizon. The implicit discount adjustments to the transaction price are due to concessions, not collectability concerns driven by payer credit risk. 4. Allocate the transaction price to performance obligations in the contract. If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. As discussed above, there is a combined performance obligation under the Company’s contracts and, therefore, the monthly transaction price determined for the performance obligation will be recognized over time ratably over the monthly term of the treatment. 5. Recognize revenue when or as the Company satisfies a performance obligation. The Company satisfies performance obligations over time. Revenue is recognized at the time the related performance obligation is satisfied by transferring a promised service to a patient. The patient consumes the benefits of treatment on a daily basis over the monthly term. As this criterion is met, the revenues will be recognized over the monthly term. For more information, see Note 2(x). Revenues are presented net of indirect taxes. Net revenues in the years ended December 31, 2021, 2020 and 2019 also include amounts recognized pursuant to the Zai Agreement. For additional information, see Note 12. |
Charitable care | Charitable care:The Company provides treatment at no charge to patients who meet certain criteria under its charitable care policy. Because the Company does not pursue collection of amounts determined to qualify as charity, they are not reported as revenue. The Company's costs of care provided under charitable care were $4,204, $3,653 and $2,847 for the years ended December 31, 2021, 2020 and 2019, respectively. These amounts were determined by applying charitable care as a percentage of gross billings to total cost of goods sold. |
Shipping and handling costs | Shipping and handling costs:The Company does not separately bill its customers for shipping and handling costs associated with shipping Products to its customers. These direct shipping and handling costs of $2,958, $3,224 and $2,688 for the years ended December 31, 2021, 2020 and 2019, respectively, are included in Sales and Marketing costs. |
Accounting for share-based compensation | Accounting for share-based compensation: The Company accounts for share-based compensation in accordance with ASC 718, "Compensation—Stock Compensation." ASC 718 requires companies to estimate the fair value of share-based compensation awards on the date of grant using an option-pricing model. The value of the award is recognized as an expense over the requisite service periods in the Company’s consolidated statements of operations. The Company's policy is to account for forfeitures as they occur. The Company recognizes compensation costs for the value of awards granted using the accelerated method over the requisite service period of the award, which is generally the restricted share unit vesting term of three years and option vesting term of four years, respectively. The Company applies the Black-Scholes model as it believes it is the most appropriate fair value method for all equity awards and for the Employee Share Purchase Plan (the "ESPP"). For market condition awards, the Company also applies the Monte-Carlo simulation model. The Black-Scholes model requires a number of assumptions, of which the most significant are the share price, expected volatility and the expected award term. Beginning with the first quarter of 2021, the computation of expected volatility is based on a combination of actual historical share price volatility of comparable publicly-traded companies and the historical volatility the Company's shares. Prior to the first quarter of 2021, due to the lack of sufficient historical information for the Company, the computation was based on actual historical volatility of comparable publicly-traded companies. Beginning with the first quarter of 2021, the expected term of options granted is calculated using the Company's historical and future exercise behavior. Prior to the first quarter of 2021, it was calculated using the average between the vesting period and the contractual term to the expected term of the options in effect at the time of grant. The Company has historically not paid dividends and has no foreseeable plans to pay dividends and, therefore, uses an expected dividend yield of zero in the option pricing model. The risk-free interest rate is based on the yield of U.S. treasury bonds with equivalent terms. |
Fair value of financial instruments | Fair value of financial instruments: The carrying amounts of cash and cash equivalents, short-term investments, restricted cash, receivables and prepaid expenses, trade receivables, trade payables and other accounts payable and accrued expenses approximate their fair value due to the short-term maturity of such instruments. The Company accounts for certain assets and liabilities at fair value under ASC 820, "Fair Value Measurements and Disclosures." Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. The Company categorizes each of its fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. The three levels of inputs that may be used to measure fair value are as follows: Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets; Level 2 - Includes other inputs that are directly or indirectly observable in the marketplace, other than quoted prices included in Level 1, such as quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets with insufficient volume or infrequent transactions, or other inputs that are observable (model-derived valuations in which significant inputs are observable), or can be derived principally from or corroborated by observable market data; and Level 3 - Unobservable inputs which are supported by little or no market activity. The availability of observable inputs can vary from instrument to instrument and is affected by a wide variety of factors, including, for example, the type of instrument, the liquidity of markets and other characteristics particular to the transaction. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment and the instrument is categorized as Level 3. |
Basic and diluted net loss per share | Basic and diluted net loss per share:Basic net income (loss) per share is computed based on the weighted average number of ordinary shares outstanding during each period. Diluted net income per share is computed based on the weighted average number of ordinary shares outstanding during the period, plus potential dilutive shares considered outstanding during the period, in accordance with ASC 260-10, as determined under the treasury stock method. |
Income taxes | Income taxes: The Company accounts for income taxes in accordance with ASC 740-10, "Income Taxes." ASC 740-10 prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, to reduce deferred tax assets to their estimated realizable value, if needed. The Company established reserves for uncertain tax positions based on the evaluation of whether or not the Company’s uncertain tax position is "more likely than not" to be sustained upon examination. The Company records interest and penalties pertaining to its uncertain tax positions in the financial statements as income tax expense. |
Concentration of risks | Concentration of risks: Our cash, cash equivalents, short-term investments and trade receivables are potentially subject to a concentration of risk. Cash, cash equivalents and short-term investments are invested at top tier financial institutions globally. As such, these investments may be in excess of insured limitations or not insured in certain jurisdictions. Generally, these investments may be redeemed upon demand and therefore, bear minimal risk. Our trade receivables are due from numerous governments and federal and state agencies that are paid from their respective budgets, and from hundreds of health insurance companies. The Company does not believe that there are significant default risks associated with these governments, agencies and health insurance companies based upon the Company's the historical experience with them. The Company has no off-balance sheet concentrations of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements. |
Retirement, pension and severance plans | Retirement, pension and severance plans: The Company has a 401(k) retirement savings plan for its U.S. employees. Each eligible employee may elect to contribute a portion of the employee’s compensation to the plan. Company contributions to the plan are at the sole discretion of the Company's Board of Directors. Currently, the Company provides a matching contribution of 50% of the employee's contributions, up to a maximum of three percent (3%) of the employee's annual salary. The Company began making matching contributions as of January 1, 2019. For the years ended December 31, 2021, 2020 and 2019, the Company had made matching contributions in the amount of $1,967 and $1,589 and $978, respectively, pursuant to the plan. The Company sponsors a defined benefit plan (the "Swiss Plan") for all its employees in Switzerland for retirement benefits, as well as benefits on death or long-term disability, whereby the employee and the Company contribute a portion of the employee's compensation to the plan. The Swiss Plan is part of a collective pension foundation “Asga Pensionskasse”. Asga is an autonomous pension foundation, meaning that the underlying investment risk and the all biometrical risks (disability, death, longevity) are born by the pension foundation itself. Notwithstanding, the Company and its employees bear the risk of having to pay recovery contributions in a financial distress situation. The Company accounts for this risk in accordance with ASC 715, "Compensation – Retirement Benefits" (see Note 9). The pension expense for the years ended December 31, 2021, 2020 and 2019 was $1,494, $1,588 and $984, respectively. Israeli law generally requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. The Company contributes to employee pension plans to fund its severance liabilities. According to Section 14 of Israel Severance Pay Law, the Company makes deposits on behalf of its employees with respect to the Company’s severance liability and therefore no obligation is provided for in the financial statements. Severance pay liabilities with respect to employees who are not subject to Section 14, are provided for in the financial statements based upon the number of years of service and the latest monthly salary and the related deposits are recorded as an asset based on the cash surrender value. Contributions pursuant to these obligations for the years ended December 31, 2021, 2020 and 2019 amounted to $1,466, $1,130 and $784, respectively. |
Contingent liabilities | Contingent liabilities: The Company accounts for its contingent liabilities in accordance with ASC 450, "Contingencies." A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. |
Other comprehensive income (loss) | Other comprehensive income (loss):The Company accounts for comprehensive income (loss) in accordance with ASC 220, "Comprehensive Income." ASC 220 establishes standards for the reporting and display of comprehensive income (loss) and its components. Comprehensive income (loss) generally represents all changes in shareholders' equity during the period except those resulting from investments by, or distributions to, shareholders. The accumulated other comprehensive income (loss), net of taxes, relates to a pension liability and foreign currency translation adjustments. |
Leases | Leases: 1. Lessee accounting: On January 1, 2019, the Company adopted ASU No. 2016-02, Leases (ASC 842). The Company determines if an arrangement is a lease and the classification of that lease at inception based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of the asset. The Company elected to not recognize a lease liability or right-of-use ("ROU") asset for leases with a term of twelve months or less. The Company also elected the practical expedient to not separate lease and non-lease components for its leases. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make minimum lease payments arising from the lease. ROU assets are initially measured at amounts, which represents the discounted present value of the lease payments over the lease, plus any initial direct costs incurred. The ROU assets are reviewed for impairment. The lease liability is initially measured at lease commencement date based on the discounted present value of minimum lease payments over the lease term. The implicit rate within the operating leases are generally not determinable; therefore, the Company uses the Incremental Borrowing Rate ("IBR") based on the information available at commencement date in determining the present value of lease payments. The Company’s IBR is estimated to approximate the interest rate on similar terms and payments and in economic environments where the leased asset is located. Certain leases include options to extend or terminate the lease. An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate is considered unless it is reasonably certain that the Company will not exercise the option. 2. Lessor accounting - Operating leases: ASC 842 provides lessors with an optional practical expedient, by class of underlying asset, not to separate non-lease components from the associated lease component and, instead, to account for those components as a single component if the non-lease components otherwise would be accounted for under the new revenue guidance (ASC 606) and both of the following criteria are met: a. The timing and pattern of transfer of the lease component and the non-lease component(s) are the same; and b. The lease component would be classified as an operating lease if it were accounted for separately. The Company's product supply agreements include the right to use the device (lease component), the supply obligation of disposable arrays and technical support for the term of treatment (non-lease component). If the lease component is the predominant component, the Company accounts for all revenues under such lease as a single component in accordance with the new lease accounting standard. Conversely, if the non-lease component is the predominant component, all revenues under such lease are accounted for in accordance with the revenue recognition accounting standard. The Company's operating leases qualify for the single component accounting, and the non-lease component in each of the Company's leases is predominant. Therefore, The Company accounts for all revenues from its operating leases in accordance with the revenue recognition accounting standard. |
Convertible note | Convertible note: Prior to January 1, 2021, the Company accounted for its convertible senior notes in accordance with ASC 470-20 "Debt with Conversion and Other Options". Pursuant to ASC Subtopic 470-20, issuers of certain convertible debt instruments, such as the convertible senior notes, that have a net settlement feature and may be settled wholly or partially in cash upon conversion are required to separately account for the liability (debt) and equity (conversion option) components of the instrument. The Company allocated the proceeds from issuance between the liability component and the embedded conversion option, or equity component. The liability component at issuance is recognized at fair value, based on the fair value of a similar instrument of similar credit rating and maturity that does not have a conversion feature. The equity component is based on the excess of the principal amount of the convertible senior notes over the fair value of the liability component and is recorded in additional paid-in capital. The equity component, net of issuance costs is presented within additional paid-in-capital and is not remeasured as long as it continues to meet the conditions for equity classification. The Company allocated the total issuance costs incurred to the liability and equity components of the convertible senior notes based on the same proportions as the proceeds from the notes. Commencing January 1, 2021, the Company early adopted ASU 2020-06, see note 2(z). |
Recently adopted and issued accounting pronouncement | Recently adopted accounting pronouncements: In August 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (ASU 2020-06), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. Among other changes, ASU 2020-06 removes from GAAP the liability and equity separation model for convertible instruments with a cash conversion feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for such debt. Similarly, the embedded conversion feature will no longer be amortized into income as interest expense over the life of the instrument. Instead, entities will account for a convertible debt instrument wholly as debt unless (1) a convertible instrument contains features that require bifurcation as a derivative under Accounting Standards Codification ("ASC Topic 815"), Derivatives and Hedging, or (2) a convertible debt instrument was issued at a substantial premium. Additionally, ASU 2020-06 requires the application of the if-converted method to calculate the impact of convertible instruments on diluted earnings per share (EPS), which is consistent with the Company’s accounting treatment under the current standard. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted for fiscal years beginning after December 15, 2020, and can be adopted on either a fully retrospective or modified retrospective basis. The Company early adopted ASU 2020-06, effective January 1, 2021 on a modified retrospective basis. The impact of the Company’s adoption of ASU 2020-06 on the balance sheet as of January 1, 2021 was an increase in long term debt, net of $128,972, a decrease in additional paid-in capital of $132,474, and a decrease in accumulated deficit of $3,502. Interest expense recognized in future periods will be reduced as a result of accounting for the convertible debt instrument as a single liability measured at its amortized cost. For additional information see Note 10 of these audited consolidated financial statements. In December 2019, the FASB issued Accounting Standard Update No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12), which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects of the current guidance. ASU 2019-12 is effective for the Company as of January 1, 2021 and the adoption of this standard did not have a material impact on the Company's consolidated financial statements. |
Basis of presentation and sig_3
Basis of presentation and significant accounting policies (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Accounting Policies [Abstract] | |
Property and Equipment at Cost Using Straight-Line Method | Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following rates: % Computers and laboratory equipment 15 - 33 Office furniture 6 - 33 Production equipment 20 Leasehold improvements Over the shorter of the term of the lease or its useful life The following table sets forth the Company’s property and equipment, net: December 31, 2021 2020 Cost: Computers and laboratory equipment $ 21,135 $ 18,821 Office furniture 3,044 2,871 Production equipment 2,377 1,628 Land and building $ 11,155 $ — Leasehold improvements 7,076 6,501 Total cost $ 44,787 $ 29,821 Accumulated depreciation and amortization (22,094) (18,426) Depreciated cost $ 22,693 $ 11,395 |
Cash and Cash equivalents and_2
Cash and Cash equivalents and Short-term investments (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Cash, Cash Equivalents, and Short-term Investments [Abstract] | |
Summary of Cash and Cash Equivalents | The Company’s cash and cash equivalents were composed of: December 31, 2021 2020 Cash $ 3,139 $ 20,339 Money market funds 64,668 214,335 Certificate of deposits, notes and term deposits 140,995 — Total cash and cash equivalents $ 208,802 $ 234,674 |
Summary of Short-Term Investments | The following table sets forth the Company’s short-term investments: December 31, 2021 2020 Term deposits $ 424,094 $ — US treasury bills 199,981 607,902 Corporate debt securities 104,823 — Total short-term investments $ 728,898 $ 607,902 |
Receivables and prepaid expen_2
Receivables and prepaid expenses (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Receivables And Prepaid Expenses [Abstract] | |
Schedule of Receivables and prepaid expenses | The following table sets forth the Company’s receivables and prepaid expenses: December 31, 2021 2020 Advances to and receivables from suppliers $ 3,843 $ 3,768 Government authorities 8,421 13,358 Prepaid expenses 4,711 3,963 Others 50 156 $ 17,025 $ 21,245 |
Inventories (Tables)
Inventories (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Inventory Disclosure [Abstract] | |
Schedule of Inventories | The following table sets forth the Company’s inventories: December 31, 2021 2020 Raw materials $ 1,485 $ 5,175 Work in process 8,274 4,896 Finished goods 14,668 17,351 $ 24,427 $ 27,422 |
Property and equipment, net (Ta
Property and equipment, net (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Property, Plant and Equipment [Abstract] | |
Schedule of Property and equipment, net | Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following rates: % Computers and laboratory equipment 15 - 33 Office furniture 6 - 33 Production equipment 20 Leasehold improvements Over the shorter of the term of the lease or its useful life The following table sets forth the Company’s property and equipment, net: December 31, 2021 2020 Cost: Computers and laboratory equipment $ 21,135 $ 18,821 Office furniture 3,044 2,871 Production equipment 2,377 1,628 Land and building $ 11,155 $ — Leasehold improvements 7,076 6,501 Total cost $ 44,787 $ 29,821 Accumulated depreciation and amortization (22,094) (18,426) Depreciated cost $ 22,693 $ 11,395 |
Field equipment, net (Tables)
Field equipment, net (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Field Equipment [Abstract] | |
Schedule of Field equipment, net | The following table sets forth the Company’s field equipment, net: December 31, 2021 2020 Field equipment $ 33,789 $ 27,876 Accumulated depreciation (20,866) (16,646) Field equipment, net $ 12,923 $ 11,230 |
Other payables and accrued ex_2
Other payables and accrued expenses (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Payables and Accruals [Abstract] | |
Schedule of Other payables and accrued expenses | The following table sets forth the Company’s other payables and accrued expenses: December 31, 2021 2020 Employees and payroll accruals $ 39,590 $ 30,316 Government authorities 5,797 5,340 Deferred revenues 17,762 17,765 Other 6,853 6,544 $ 70,002 $ 59,965 |
Employee benefit obligations (T
Employee benefit obligations (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Retirement Benefits [Abstract] | |
Schedule of Targeted Allocation for Funds | The targeted allocation for these funds is as follows: Asset Allocation by Category as of December 31, 2021: Asset allocation (%) Asset Category: Debt Securities 30% Real Estate 27% Equity Securities 37% Others 6% Total 100% |
Schedule of Change in Benefit Obligations | The following table sets forth the Swiss Plan’s funded status and amounts recognized in the consolidated financial statements for the year ended December 31, 2021 and 2020: December 31, 2021 2020 Change in Benefit Obligation Projected benefit obligation at beginning of year $ 22,753 $ 15,685 Interest cost 48 37 Company service cost 1,915 1,483 Employee contributions 1,167 870 Prior service cost (923) — Benefits paid 2,976 1,612 Actuarial loss 2,039 3,066 Projected benefit obligation at end of year $ 29,975 $ 22,753 Change in Plan Assets Fair value of plan assets at beginning of year $ 18,082 $ 12,356 Actual return on plan assets 1,992 1,938 Employer contributions 1,750 1,306 Employee contributions 1,167 870 Benefits paid 2,976 1,612 Fair value of plan assets at end of year $ 25,967 $ 18,082 Funded Status at End of year Excess of obligation over assets $ 4,008 $ 4,671 Change in Accrued Benefit Liability Accrued benefit liability at beginning of year $ (4,671) $ (3,329) Company contributions made during year 1,750 1,306 Net periodic benefit cost for year (1,310) (1,909) Net decrease (increase) in accumulated other comprehensive loss 223 (739) Accrued benefit liability at end of year $ (4,008) $ (4,671) December 31, 2021 2020 Non-current plan assets $ 25,967 $ 18,083 Non-current liability 29,975 22,754 Accrued benefit liability at end of year $ (4,008) $ (4,671) Projected Benefit Payments Projected year 1 $ 567 $ 1,804 Projected year 2 454 394 Projected year 3 819 400 Projected year 4 765 788 Projected year 5 452 405 Projected years 6-10 13,816 3,445 |
Schedule of Plan Assets Fair Value | Year ended December 31, 2021 2020 Net Periodic Benefit Cost Service cost $ 1,915 $ 1,483 Interest cost (income) 48 37 Expected return on plan assets (508) (31) Amortization of actuarial (gain) loss 133 120 Amortization of prior service costs (94) (21) Total net periodic benefit cost $ 1,494 $ 1,588 Weighted average assumptions: Discount rate as of December 31 0.20% 0.20 % Expected long-term rate of return on assets 2.50% 0.20 % Rate of compensation increase 1.00% 1.00% Mortality and disability assumptions (*) BVG 2020 GT BVG 2015 GT (*) Mortality data used for actuarial calculation. |
Long-term debt, net (Tables)
Long-term debt, net (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Debt Disclosure [Abstract] | |
Summary of Long-term Debt, Net | The following table sets forth the Company’s long-term debt, net: December 31, 2021 2020 0% Convertible Senior Notes (a) $ 562,216 $ 429,905 Credit facility (b) — — $ 562,216 $ 429,905 |
Summary of the Convertible Notes | The net carrying amount of the liability and equity components of the Convertible Notes (see note 2(z) for additional information) as of December 31, 2021 and 2020 are as follows: December 31, 2021 2020 Liability component, net: Principal amount $ 575,000 $ 575,000 Unamortized discount — (132,797) Unamortized issuance costs (12,784) (12,298) Net carrying amount of liability component (1) $ 562,216 $ 429,905 Equity component, net: Conversion feature $ — $ 136,402 Issuance costs $ — (3,928) Net carrying amount of equity component $ — $ 132,474 (1) An effective interest rate determines the fair value of the Notes, therefore they are categorized as Level 3 in accordance with ASC 820, "Fair Value Measurements and Disclosures." The estimated fair value of the Net carrying amount of liability component of the Notes as of December 31, 2021 and 2020 were $467,469 and $450,437, respectively. Finance expense related to the Notes were as follows: Year ended December 31, 2021 2020 Amortization of debt issuance costs $ 3,339 $ 333 Amortization of debt discount $ — $ 3,605 Total finance expense recognized $ 3,339 $ 3,938 |
Other long-term liabilities (Ta
Other long-term liabilities (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Other Liabilities Disclosure [Abstract] | |
Schedule of Other long-term liabilities | December 31, 2021 2020 Leasehold improvements financing and other $ 12 $ 40 Unrecognized tax benefits (Note 13(e)) 154 297 $ 166 $ 337 |
Commitments and contingent li_2
Commitments and contingent liabilities (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | |
Schedule of Future Minimum Lease Payments under Non-Cancelable Operating Lease | The corresponding lease liabilities are split between other payables and long-term lease liabilities, and as of December 31, 2021, are as follows: December 31, 2021 Future minimum lease payments: 2022 $ 6,925 2023 4,959 2024 3,508 2025 2,083 2026 1,990 Thereafter 2,511 Total future minimum lease payments $ 21,976 Less imputed interest (2,295) Net present value of future minimum lease payments $ 19,681 Current year end Short-term lease liabilities $ 6,684 Long-term lease liabilities 12,997 Net present value of future minimum lease payments $ 19,681 Weighted average of remaining operating lease term (years) 4.47 Weighted average of operating lease discount rate 5.62 % |
Income taxes (Tables)
Income taxes (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Income Tax Disclosure [Abstract] | |
Schedule of Income (Loss) before Income Taxes | Income (loss) before income taxes is as follows: Year ended December 31, 2021 2020 2019 United States (U.S.) $ 82,249 $ (15,283) $ (87,925) Non-U.S. (134,324) 33,385 79,101 Total income (loss) before income taxes $ (52,075) $ 18,102 $ (8,824) |
Schedule of Components of Income Tax Expense (Benefit) | The provision (benefit) for income taxes from continuing operations is comprised of: Year ended December 31, 2021 2020 2019 Current: U.S. $ 65 $ (11,898) $ (6,143) Non-U.S. 6,211 10,192 4,405 Total current $ 6,276 $ (1,706) $ (1,738) Deferred: Non-U.S. — — 144 Total deferred — — 144 Total income tax provision $ 6,276 $ (1,706) $ (1,594) |
Reconciliation of Provision for Income Taxes | A reconciliation of the provision for income taxes compared with the amounts at the notional federal statutory rate was: Year ended December 31, 2021 2020 2019 Income (loss) before income taxes $ (52,075) $ 18,102 $ (8,824) U.S. statutory income tax rate 21.0 % 21.0 % 21.0 % Notional U.S. federal income taxes at statutory rate $ (10,936) $ 3,801 $ (1,853) Foreign taxes rate differential 14,651 4,024 (4,216) Share based compensation (12,669) (6,190) (26,528) Change in valuation allowance 11,643 6,821 244,344 Return to provision true-ups 2,416 654 (5,204) Research and Development Credits (2,216) (5,243) (2,333) State income taxes 1,572 607 (16,679) Withholding Taxes 273 2,366 384 Non-deductible expenses (147) 260 357 Unamortized intangible assets — — (189,410) 2020 Cares Act — (8,694) — Other 1,689 (112) (456) Income tax $ 6,276 $ (1,706) $ (1,594) Effective tax rate (12.1) % (9.4) % 18.1 % |
Schedule of Significant Components of Deferred Tax Assets and Liabilities | Significant components of the Company’s deferred tax assets and liabilities are as follows: December 31, 2021 2020 Deferred tax assets: Unamortized intangible assets $ 138,978 $ 157,930 Impact of revenue recognition $ 112,251 $ 131,395 Net operating loss carryforwards $ 77,664 $ 40,314 Share based compensation $ 25,644 $ 17,595 Research and development $ 12,146 $ 9,186 Interest limitations $ 7,948 $ 6,975 Lease liability $ 4,836 $ 1,006 Other temporary differences $ 3,032 $ 2,822 Total gross deferred tax assets $ 382,499 $ 367,223 Less: valuation allowance (375,717) (364,082) Total deferred tax assets 6,782 3,141 Deferred tax liabilities: Right of use assets 4,559 936 Fixed assets 2,214 2,185 Other liabilities 9 20 Total gross deferred tax liabilities $ 6,782 $ 3,141 Net deferred taxes assets (liability) $ — $ — |
Schedule of Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits | A reconciliation of the beginning and ending balances of uncertain tax benefits is as follows: December 31, 2021 2020 2019 Balance at beginning of the year $ 297 $ 116 $ 103 Additions (reductions) for taxes positions related to prior years (143) 181 13 Balance at the end of the year $ 154 $ 297 $ 116 |
Share capital (Tables)
Share capital (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract] | |
Schedule of Share Capital | Share capital is composed as follows: Issued and outstanding Number of shares December 31, 2021 2020 Ordinary shares no par value 103,971,263 102,334,276 |
Schedule of Fair Value Assumptions Used for All Equity Based Awards Estimated Using Black-Scholes Option Pricing Model | The fair value of share-based awards was estimated using the Black-Scholes model for all equity grants and for market condition awards. The Company also applied the Monte-Carlo simulation model, with the following underlying assumptions: Year ended December 31, 2021 2020 2019 Stock Option Plans Expected term (years) 5.50-6.00 5.50-6.00 5.50-6.00 Expected volatility 60%-63% 54%-56% 55%-61% Risk-free interest rate 0.78%-1.27% 0.30%-0.86% 1.73%-2.40% Dividend yield 0.00 % 0.00 % 0.00 % ESPP Expected term (years) 0.50 0.50 0.50 Expected volatility 54%-81% 47%-66% 44%-62% Risk-free interest rate 0.05%-0.09% 0.17%-1.57% 2.10%-2.51% Dividend yield 0.00 % 0.00 % 0.00 % |
Schedule of Stock Options to Purchase Ordinary Shares | A summary of the status of the Company’s options to purchase ordinary shares as of December 31, 2021 and changes during the year ended on that date is presented below: Year ended December 31, 2021 Number of options Weighted average exercise price Aggregate intrinsic value Outstanding at beginning of year 9,220,326 $ 26.21 Granted 466,360 149.96 Exercised (1,016,369) 20.81 Forfeited and cancelled (120,995) 62.77 Outstanding at end of year 8,549,322 $ 33.09 $ 394,997 Exercisable options 5,145,149 $ 19.76 $ 285,295 |
Schedule of RSUs and PSUs | A summary of the status of the Company’s RSUs and PSUs as of December 31, 2021 and changes during the year ended on that date is presented below: Year ended December 31, 2021 Number of Weighted average grant date fair value price Aggregate intrinsic value Unvested at beginning of year 4,466,151 $ 54.06 Granted 632,275 138.37 Vested (569,248) 52.63 Forfeited and cancelled (70,071) 94.41 Unvested at end of year (1) 4,459,107 $ 65.56 $ 334,790 (1) Includes PSUs that have a mix of service, market and other milestone performance vesting conditions which are vested upon achievements of market and performance conditions which are not probable, as of December 31, 2021, in accordance with ASC 718 as follows: December 31, 2021 Number of Fair value at grant date per PSU Total fair value at grant date 2,703,852 $ 48.16 $ 130,218 108,113 69.37 7,500 17,712 84.68 1,500 10,532 94.94 1,000 189,626 $ 114.26 $ 21,667 3,029,835 $ 161,885 |
Schedule of Equity-Based Compensation Expenses Related to Company's Equity-Based Awards | The total equity-based compensation expense related to all of the Company’s equity incentive plans recognized for the years ended December 31, 2021, 2020 and 2019, was comprised as follows: Year ended December 31, 2021 2020 2019 Cost of revenues $ 3,471 $ 2,221 $ 2,231 Research, development and clinical studies 27,597 18,125 7,570 Sales and marketing 22,673 17,672 11,897 General and administrative 41,159 37,703 30,718 Total share-based compensation expense $ 94,900 $ 75,721 $ 52,416 |
Schedule of Stock Option Outstanding | Options outstanding as of December 31, 2021 are as follows: Exercise price Number of options outstanding Weighted average remaining contractual term Number of options exercisable Weighted average remaining contractual term $ (years) (years) 0.00 - 10.00 1,116,075 4.48 1,116,075 4.48 10.01 - 20.00 2,668,814 4.94 1,787,295 4.74 20.01 - 30.00 1,886,852 5.53 1,461,424 5.35 30.01 - 40.00 331,417 6.56 272,217 6.54 40.01 - 60.00 1,200,783 7.29 274,740 7.21 60.01 - 100.00 871,555 8.18 227,804 8.13 100.01 - 160.00 462,606 9.25 5,594 8.85 160.01 - 220.00 11,220 9.42 — 0.00 8,549,322 5.97 5,145,149 5.24 |
Financial expenses, net (Tables
Financial expenses, net (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Interest and Debt Expense [Abstract] | |
Schedule of Financial expenses, net | The following table sets forth the Company’s total financial expenses, net: Year ended December 31, 2021 2020 2019 Financial expenses: Interest expense $ (101) $ (13,068) $ (13,718) Revolving credit facility fee (588) (79) — Amortization of discount and issuance costs (3,339) (4,514) (156) Foreign currency transaction losses (4,032) — (431) Others (779) (389) (338) $ (8,839) $ (18,050) $ (14,643) Financial income: Amortization of investments premium $ 306 $ 1,316 $ 2,331 Foreign currency transaction gains — 2,648 — Interest income 791 1,787 4,402 $ 1,097 $ 5,751 $ 6,733 Total financial expenses, net $ (7,742) $ (12,299) $ (7,910) |
Basic and diluted net income _2
Basic and diluted net income (loss) per share (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Earnings Per Share [Abstract] | |
Schedule of Basic and diluted net income (loss) per ordinary share | The following table sets forth the computation of the Company’s basic and diluted net loss per ordinary share: Year ended December 31, 2021 2020 2019 Net income (loss) attributable to ordinary shares as reported $ (58,351) $ 19,808 $ (7,230) Net income (loss) used in computing basic net income (loss) per share $ (58,351) $ 19,808 $ (7,230) Adjustment needed in calculating diluted net income (loss) per share — — — Net income (loss) used in computing diluted net income (loss) per share $ (58,351) $ 19,808 $ (7,230) Weighted average number of ordinary shares used in computing basic net income (loss) per share 103,433,274 100,930,866 97,237,549 Potentially dilutive shares that were excluded from the computation of basic net income (loss) per share: Options — 6,967,554 — Restricted share units — 945,612 — ESPP — 33,616 — Weighted average number of ordinary shares used in computing diluted net income (loss) per share 103,433,274 108,877,648 97,237,549 Weighted anti-dilutive shares outstanding which were not included in the diluted calculation 8,524,922 1,307,762 10,230,982 Basic net income (loss) per ordinary share $ (0.56) $ 0.20 $ (0.07) Diluted net income (loss) per ordinary share $ (0.56) $ 0.18 $ (0.07) |
Supplemental information (Table
Supplemental information (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Geographic Areas, Long-Lived Assets [Abstract] | |
Schedule of Long-lived assets by location | The following table presents long-lived assets by location: December 31, 2021 2020 United States $ 23,263 $ 11,868 Israel 5,297 4,370 Switzerland 4,085 2,849 Germany 1,020 1,075 Japan 799 1,230 Others 1,152 1,233 Total long-lived assets $ 35,616 $ 22,625 |
Schedule of Revenues by geographic region | The Company’s net revenues by geographic region, based on the patient’s location are summarized as follows: Year ended December 31, 2021 2020 2019 United States $ 353,110 $ 340,782 $ 232,805 EMEA: Germany 93,939 93,264 86,564 Other EMEA 30,577 18,654 8,782 Japan 34,640 29,076 17,912 Greater China (1) 22,765 12,590 5,255 Total net revenues $ 535,031 $ 494,366 $ 351,318 (1) For additional information, see Note 12. |
Selected quarterly financial _2
Selected quarterly financial information (Unaudited) (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Selected Quarterly Financial Information [Abstract] | |
Summary of Selected quarterly financial information (Unaudited) | The following table sets forth selected financial information for the Company: 2021 Three months ended December 31 September 30 June 30 March 31 Net revenues $ 133,213 $ 133,606 $ 133,517 $ 134,695 Gross profit 103,526 103,400 104,918 108,310 Operating income (loss) (23,398) (8,552) (12,295) (88) Net income (loss) (26,458) (13,124) (14,641) (4,128) Basic net income (loss) per ordinary share $ (0.25) $ (0.13) $ (0.14) $ (0.04) Weighted average number of ordinary shares used in computing basic net income (loss) per share 103,884,288 103,731,147 103,484,866 102,633,545 Diluted net income (loss) per ordinary share $ (0.25) $ (0.13) $ (0.14) $ (0.04) Weighted average number of ordinary shares used in computing diluted net income (loss) per share 103,884,288 103,731,147 103,484,866 102,633,545 2020 Three months ended December 31 September 30 June 30 March 31 Net revenues $ 143,953 $ 132,660 $ 115,925 $ 101,828 Gross profit 115,817 104,265 90,451 77,332 Operating income (loss) 12,092 15,022 6,668 (3,381) Net income (loss) 4,917 9,284 1,655 3,952 Basic net income (loss) per ordinary share $ 0.05 $ 0.09 $ 0.02 $ 0.04 Weighted average number of ordinary shares used in computing basic net income (loss) per share 101,945,085 101,234,306 100,718,893 99,877,567 Diluted net income (loss) per ordinary share $ 0.04 $ 0.09 $ 0.02 $ 0.04 Weighted average number of ordinary shares used in computing diluted net income (loss) per share 110,604,714 108,643,814 107,647,802 108,100,623 2019 Three months ended December 31 September 30 June 30 March 31 Net revenues $ 99,234 $ 92,062 $ 86,713 $ 73,309 Gross profit 74,448 69,162 65,607 53,495 Operating income (loss) 153 3,855 1,196 (6,118) Net income (loss) 4,260 1,930 (1,270) (12,150) Basic net income (loss) per ordinary share $ 0.04 $ 0.02 $ (0.01) $ (0.13) Weighted average number of ordinary shares used in computing basic net income (loss) per share 99,226,445 98,485,519 96,356,317 94,811,282 Diluted net income (loss) per ordinary share $ 0.04 $ 0.02 $ (0.01) $ (0.13) Weighted average number of ordinary shares used in computing diluted net income (loss) per share 107,911,519 107,604,578 96,356,317 94,811,282 |
Basis of presentation and sig_4
Basis of presentation and significant accounting policies - Additional Information (Details) - USD ($) $ in Thousands | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Significant Accounting Policies [Line Items] | ||||
Allowance for credit losses | $ 0 | $ 0 | $ 0 | |
Inventory write-offs | 1,045 | 616 | 310 | |
Impairment of long-lived assets | 0 | 0 | 0 | |
Cost related to charitable care | $ 4,204 | 3,653 | 2,847 | |
Expected dividend yield | 0.00% | |||
Percent of employer matching contribution | 50.00% | |||
Contributions | $ 1,967 | 1,589 | 978 | |
Pension expense | 1,494 | 1,588 | 984 | |
Severance costs | 1,466 | 1,130 | 784 | |
Stockholders' equity | 410,494 | 476,526 | 217,790 | $ 112,259 |
Additional paid-in capital | ||||
Significant Accounting Policies [Line Items] | ||||
Stockholders' equity | 1,099,589 | 1,111,435 | 871,442 | 757,314 |
Retained earnings (accumulated deficit) | ||||
Significant Accounting Policies [Line Items] | ||||
Stockholders' equity | $ (685,926) | (631,077) | $ (650,885) | $ (643,655) |
Cumulative Effect, Period of Adoption, Adjustment | ||||
Significant Accounting Policies [Line Items] | ||||
Stockholders' equity | (128,972) | |||
Cumulative Effect, Period of Adoption, Adjustment | Additional paid-in capital | ||||
Significant Accounting Policies [Line Items] | ||||
Stockholders' equity | (132,474) | |||
Cumulative Effect, Period of Adoption, Adjustment | Retained earnings (accumulated deficit) | ||||
Significant Accounting Policies [Line Items] | ||||
Stockholders' equity | $ 3,502 | |||
Restricted Share Unit | ||||
Significant Accounting Policies [Line Items] | ||||
Stock awards granted, vesting period | 3 years | |||
Options | ||||
Significant Accounting Policies [Line Items] | ||||
Stock awards granted, vesting period | 4 years | |||
Expected dividend yield | 0.00% | 0.00% | 0.00% | |
Shipping and Handling | ||||
Significant Accounting Policies [Line Items] | ||||
Direct costs included in sales and marketing costs | $ 2,958 | $ 3,224 | $ 2,688 | |
Field equipment under operating leases | ||||
Significant Accounting Policies [Line Items] | ||||
Equipment write-downs included in cost of revenue | $ 639 | $ 409 | $ 327 | |
Minimum | Field equipment under operating leases | ||||
Significant Accounting Policies [Line Items] | ||||
Property and equipment useful life | 18 months | |||
Maximum | ||||
Significant Accounting Policies [Line Items] | ||||
Employer matching contribution, percent of employees' annual salary | 3.00% | |||
Maximum | Field equipment under operating leases | ||||
Significant Accounting Policies [Line Items] | ||||
Property and equipment useful life | 36 months |
Basis of presentation and sig_5
Basis of presentation and significant accounting policies - Property and Equipment at Cost Using Straight-Line Method (Details) | 12 Months Ended |
Dec. 31, 2021 | |
Computers and laboratory equipment | Minimum | |
Property, Plant and Equipment [Line Items] | |
Straight line depreciation rate | 15.00% |
Computers and laboratory equipment | Maximum | |
Property, Plant and Equipment [Line Items] | |
Straight line depreciation rate | 33.00% |
Office furniture | Minimum | |
Property, Plant and Equipment [Line Items] | |
Straight line depreciation rate | 6.00% |
Office furniture | Maximum | |
Property, Plant and Equipment [Line Items] | |
Straight line depreciation rate | 33.00% |
Production equipment | |
Property, Plant and Equipment [Line Items] | |
Straight line depreciation rate | 20.00% |
Cash and Cash equivalents and_3
Cash and Cash equivalents and Short-term investments- Summary of Cash and Cash Equivalents (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Cash and Cash Equivalents [Line Items] | ||
Cash and cash equivalents | $ 208,802 | $ 234,674 |
Cash | ||
Cash and Cash Equivalents [Line Items] | ||
Cash and cash equivalents | 3,139 | 20,339 |
Money market funds | ||
Cash and Cash Equivalents [Line Items] | ||
Cash and cash equivalents | 64,668 | 214,335 |
Certificate of deposits, notes and term deposits | ||
Cash and Cash Equivalents [Line Items] | ||
Cash and cash equivalents | $ 140,995 | $ 0 |
Cash and Cash equivalents and_4
Cash and Cash equivalents and Short-term investments - Summary of Short-Term Investments (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Restricted Cash and Cash Equivalents Items [Line Items] | ||
Short-term investments | $ 728,898 | $ 607,902 |
Term deposits | ||
Restricted Cash and Cash Equivalents Items [Line Items] | ||
Short-term investments | 424,094 | 0 |
US treasury bills | ||
Restricted Cash and Cash Equivalents Items [Line Items] | ||
Short-term investments | 199,981 | 607,902 |
Corporate debt securities | ||
Restricted Cash and Cash Equivalents Items [Line Items] | ||
Short-term investments | $ 104,823 | $ 0 |
Cash and Cash equivalents and_5
Cash and Cash equivalents and Short-term investments - Additional Information (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Cash and Cash Equivalents [Line Items] | ||
Estimated fair value of short-term investments | $ 728,906 | $ 607,905 |
Fair value, inputs, level 1 | ||
Cash and Cash Equivalents [Line Items] | ||
Estimated fair value of short-term investments | $ 624,083 | $ 607,905 |
Receivables and prepaid expen_3
Receivables and prepaid expenses - Schedule of Receivables and prepaid expenses (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Receivables And Prepaid Expenses [Abstract] | ||
Advances to and receivables from suppliers | $ 3,843 | $ 3,768 |
Government authorities | 8,421 | 13,358 |
Prepaid expenses | 4,711 | 3,963 |
Others | 50 | 156 |
Receivables and prepaid expenses | $ 17,025 | $ 21,245 |
Inventories (Details)
Inventories (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Inventory Disclosure [Abstract] | ||
Raw materials | $ 1,485 | $ 5,175 |
Work in process | 8,274 | 4,896 |
Finished goods | 14,668 | 17,351 |
Inventories | $ 24,427 | $ 27,422 |
Property and equipment, net - S
Property and equipment, net - Schedule of Property and equipment, net (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | $ 44,787 | $ 29,821 |
Accumulated depreciation and amortization | (22,094) | (18,426) |
Depreciated cost | 22,693 | 11,395 |
Computers and laboratory equipment | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | 21,135 | 18,821 |
Office furniture | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | 3,044 | 2,871 |
Production equipment | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | 2,377 | 1,628 |
Land and building | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | 11,155 | 0 |
Leasehold improvements | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | $ 7,076 | $ 6,501 |
Property and equipment, net - A
Property and equipment, net - Additional Information (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Property, Plant and Equipment [Abstract] | |||
Computer software capitalized | $ 9,979 | $ 9,219 | |
Computer software amortized | 1,084 | 1,398 | $ 1,682 |
Depreciation expense | $ 2,812 | $ 2,635 | $ 2,080 |
Field equipment, net - Schedule
Field equipment, net - Schedule of Field equipment, net (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Field Equipment [Abstract] | ||
Field equipment | $ 33,789 | $ 27,876 |
Accumulated depreciation | (20,866) | (16,646) |
Field equipment, net | $ 12,923 | $ 11,230 |
Field equipment, net - Addition
Field equipment, net - Additional Information (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Field Equipment [Line Items] | |||
Depreciation expense | $ 2,812 | $ 2,635 | $ 2,080 |
Field equipment | |||
Field Equipment [Line Items] | |||
Depreciation expense | 6,355 | 5,117 | 4,631 |
Field equipment under operating leases | |||
Field Equipment [Line Items] | |||
Write downs | $ 639 | $ 409 | $ 327 |
Other payables and accrued ex_3
Other payables and accrued expenses - Schedule of Other payables and accrued expenses (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Payables and Accruals [Abstract] | ||
Employees and payroll accruals | $ 39,590 | $ 30,316 |
Government authorities | 5,797 | 5,340 |
Deferred revenues | 17,762 | 17,765 |
Other | 6,853 | 6,544 |
Other payables and accrued expenses | $ 70,002 | $ 59,965 |
Employee benefit obligations -
Employee benefit obligations - Schedule of Asset Allocation by Category (Details) | Dec. 31, 2021 |
Defined Benefit Plan Disclosure [Line Items] | |
Target asset allocations | 100.00% |
Debt Securities | |
Defined Benefit Plan Disclosure [Line Items] | |
Target asset allocations | 30.00% |
Real Estate | |
Defined Benefit Plan Disclosure [Line Items] | |
Target asset allocations | 27.00% |
Equity Securities | |
Defined Benefit Plan Disclosure [Line Items] | |
Target asset allocations | 37.00% |
Others | |
Defined Benefit Plan Disclosure [Line Items] | |
Target asset allocations | 6.00% |
Employee benefit obligations _2
Employee benefit obligations - Net Funded Status (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Change in Benefit Obligation | ||
Projected benefit obligation at beginning of year | $ 22,753 | $ 15,685 |
Interest cost | 48 | 37 |
Company service cost | 1,915 | 1,483 |
Employee contributions | 1,167 | 870 |
Prior service cost | (923) | 0 |
Benefits paid | 2,976 | 1,612 |
Actuarial loss | 2,039 | 3,066 |
Projected benefit obligation at end of year | 29,975 | 22,753 |
Change in Plan Assets | ||
Fair value of plan assets at beginning of year | 18,082 | 12,356 |
Actual return on plan assets | 1,992 | 1,938 |
Employer contributions | 1,750 | 1,306 |
Employee contributions | 1,167 | 870 |
Benefits paid | 2,976 | 1,612 |
Fair value of plan assets at end of year | 25,967 | 18,082 |
Funded Status at End of year | ||
Excess of obligation over assets | 4,008 | 4,671 |
Change in Accrued Benefit Liability | ||
Accrued benefit liability at beginning of year | (4,671) | (3,329) |
Company contributions made during year | 1,750 | 1,306 |
Net periodic benefit cost for year | (1,310) | (1,909) |
Net decrease (increase) in accumulated other comprehensive loss | 223 | (739) |
Accrued benefit liability at end of year | (4,008) | (4,671) |
Non-current plan assets | 25,967 | 18,083 |
Non-current liability | 29,975 | 22,754 |
Accrued benefit liability at end of year | (4,008) | (4,671) |
Projected Benefit Payments | ||
Projected year 1 | 567 | 1,804 |
Projected year 2 | 454 | 394 |
Projected year 3 | 819 | 400 |
Projected year 4 | 765 | 788 |
Projected year 5 | 452 | 405 |
Projected years 6-10 | $ 13,816 | $ 3,445 |
Employee benefit obligations _3
Employee benefit obligations - Net Periodic Benefit Cost (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Net Periodic Benefit Cost | ||
Service cost | $ 1,915 | $ 1,483 |
Interest cost (income) | 48 | 37 |
Expected return on plan assets | (508) | (31) |
Amortization of actuarial (gain) loss | 133 | 120 |
Amortization of prior service costs | (94) | (21) |
Total net periodic benefit cost | $ 1,494 | $ 1,588 |
Weighted average assumptions: | ||
Discount rate as of December 31 | 0.20% | 0.20% |
Expected long-term rate of return on assets | 2.50% | 0.20% |
Rate of compensation increase | 1.00% | 1.00% |
Long-term debt, net - Summary o
Long-term debt, net - Summary of Long-term Debt, Net (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 | Nov. 05, 2020 | Feb. 07, 2018 |
Debt Instrument [Line Items] | ||||
Net long-term debt | $ 562,216 | $ 429,905 | ||
the “Notes” | Convertible Debt | ||||
Debt Instrument [Line Items] | ||||
Stated interest rate | 0.00% | |||
Net long-term debt | 562,216 | 429,905 | ||
2018 Credit Facility | Medium-term Notes | ||||
Debt Instrument [Line Items] | ||||
Stated interest rate | 9.00% | |||
Net long-term debt | $ 0 | $ 0 |
Long-term debt, net - Additiona
Long-term debt, net - Additional Information (Details) | Nov. 05, 2020USD ($)day$ / shares | Aug. 18, 2020USD ($) | Jan. 31, 2021USD ($) | Dec. 31, 2021USD ($) | Dec. 31, 2020USD ($) | Dec. 31, 2019USD ($) | Feb. 07, 2018USD ($) |
Debt Instrument [Line Items] | |||||||
Proceeds from convertible note, net | $ 0 | $ 558,439,000 | $ 0 | ||||
Convertible Debt | the “Notes” | |||||||
Debt Instrument [Line Items] | |||||||
Aggregate principal amount | $ 575,000,000 | ||||||
Stated interest rate | 0.00% | ||||||
Proceeds from convertible note, net | $ 558,400,000 | ||||||
Initial conversion rate | 0.0059439 | ||||||
Initial conversion price (in usd per share) | $ / shares | $ 168.24 | ||||||
Cash portion per $1,000 principal amount of Notes converted | $ 1,000 | $ 1,000 | |||||
Percentage of ordinary shares sale price to the conversion price | 130.00% | ||||||
Number of trading days | day | 20 | ||||||
Number of consecutive trading days | day | 30 | ||||||
Redemption price, percentage of principal amount to be redeemed | 100.00% | ||||||
Sinking fund provided | $ 0 | ||||||
Covenant compliance holders, face amount | $ 3,000,000 | ||||||
Percentage of ordinary shares sale price to the conversion price | 98.00% | ||||||
Number of consecutive trading days | day | 5 | ||||||
Number of threshold days | day | 10 | ||||||
Threshold percentage of stock price trigger | 10.00% | ||||||
Notice period | day | 35 | ||||||
Debt instrument, un-amortized issuance costs | $ 12,784,000 | $ 12,298,000 | |||||
Medium-term Notes | 2018 Credit Facility | |||||||
Debt Instrument [Line Items] | |||||||
Aggregate principal amount | $ 150,000,000 | ||||||
Stated interest rate | 9.00% | ||||||
Debt principal repayment | $ 150,000,000 | ||||||
Debt prepayment premium | 3,000,000 | ||||||
Debt instrument, un-amortized issuance costs | $ 478,000 |
Long-term debt, net - Liability
Long-term debt, net - Liability and Equity Components of the Convertible Notes (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Debt Instrument [Line Items] | ||
Net carrying amount of liability component | $ 562,216 | $ 429,905 |
Convertible Debt | the “Notes” | ||
Debt Instrument [Line Items] | ||
Principal amount | 575,000 | 575,000 |
Unamortized discount | 0 | (132,797) |
Unamortized issuance costs | (12,784) | (12,298) |
Net carrying amount of liability component | 562,216 | 429,905 |
Conversion feature | 0 | 136,402 |
Issuance costs | 0 | (3,928) |
Net carrying amount of equity component | 0 | 132,474 |
Estimated fair value | $ 467,469 | $ 450,437 |
Long-term debt, net - Finance E
Long-term debt, net - Finance Expense Related to the Convertible Notes (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Debt Instrument [Line Items] | |||
Amortization of debt discount | $ 3,101 | $ 3,260 | $ (2,176) |
the “Notes” | Convertible Debt | |||
Debt Instrument [Line Items] | |||
Amortization of debt issuance costs | 3,339 | 333 | |
Amortization of debt discount | 0 | 3,605 | |
Total finance expense recognized | $ 3,339 | $ 3,938 |
Other long-term liabilities - S
Other long-term liabilities - Schedule of Other long-term liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Other Liabilities Disclosure [Abstract] | ||
Leasehold improvements financing and other | $ 12 | $ 40 |
Unrecognized tax benefits | 154 | 297 |
Other long-term liabilities | $ 166 | $ 337 |
Commitments and contingent li_3
Commitments and contingent liabilities - Schedule of Future Minimum Lease Payments under Non-Cancelable Operating Leases (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Future minimum lease payments: | ||
2022 | $ 6,925 | |
2023 | 4,959 | |
2024 | 3,508 | |
2025 | 2,083 | |
2026 | 1,990 | |
Thereafter | 2,511 | |
Total future minimum lease payments | 21,976 | |
Less imputed interest | (2,295) | |
Net present value of future minimum lease payments | 19,681 | |
Short-term lease liabilities | 6,684 | |
Long-term lease liabilities | 12,997 | $ 14,293 |
Net present value of future minimum lease payments | $ 19,681 | |
Weighted average of remaining operating lease term (years) | 4 years 5 months 19 days | |
Weighted average of operating lease discount rate | 5.62% | |
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] | Other payables, lease liabilities and accrued expenses |
Commitments and contingent li_4
Commitments and contingent liabilities - Additional Information (Details) - USD ($) $ in Thousands | Nov. 06, 2020 | Sep. 10, 2018 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 |
Loss Contingencies [Line Items] | |||||
Lease and rental expense | $ 7,349 | $ 5,950 | $ 5,410 | ||
Pledged bank deposits | 2,350 | 1,438 | |||
Operating lease commitments | 2,698 | 1,687 | |||
Zai License and Collaboration Agreement | |||||
Loss Contingencies [Line Items] | |||||
Non-refundable up-front license fee, amount | $ 15,000 | ||||
Zai License and Collaboration Agreement | License | |||||
Loss Contingencies [Line Items] | |||||
Regulatory and commercial milestone payments | 10,000 | ||||
Liability, revenue recognized | $ 6,308 | $ 3,981 | $ 2,115 | ||
Zai License and Collaboration Agreement | License | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2021-01-01 | |||||
Loss Contingencies [Line Items] | |||||
Revenue recognition period | 6 years | ||||
Minimum | Zai License and Collaboration Agreement | License | |||||
Loss Contingencies [Line Items] | |||||
Percentage of tiered royalties rates on net sales | 10.00% | ||||
Maximum | Zai License and Collaboration Agreement | |||||
Loss Contingencies [Line Items] | |||||
Regulatory and commercial milestone payments | $ 78,000 | ||||
Line of Credit | Revolving Credit Facility | |||||
Loss Contingencies [Line Items] | |||||
Contractual term | 3 years | ||||
Maximum borrowing capacity | $ 150,000 | ||||
Covenant compliance, maximum outstanding commitments | $ 250,000 | ||||
Outstanding balance borrowed under the facility | $ 0 | ||||
Line of Credit | Minimum | Revolving Credit Facility | |||||
Loss Contingencies [Line Items] | |||||
Fee for unused revolving credit commitments, percentage | 0.35% | ||||
Line of Credit | Minimum | Revolving Credit Facility | London Interbank Offered Rate (LIBOR) | |||||
Loss Contingencies [Line Items] | |||||
Basis spread on variable rate | 2.75% | ||||
Line of Credit | Maximum | Revolving Credit Facility | |||||
Loss Contingencies [Line Items] | |||||
Fee for unused revolving credit commitments, percentage | 0.45% | ||||
Line of Credit | Maximum | Revolving Credit Facility | London Interbank Offered Rate (LIBOR) | |||||
Loss Contingencies [Line Items] | |||||
Basis spread on variable rate | 3.25% |
Income taxes - Schedule of Inco
Income taxes - Schedule of Income (Loss) before Income Taxes, Domestic and Foreign (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Income Tax Disclosure [Abstract] | |||
United States (U.S.) | $ 82,249 | $ (15,283) | $ (87,925) |
Non-U.S. | (134,324) | 33,385 | 79,101 |
Income (loss) before income taxes | $ (52,075) | $ 18,102 | $ (8,824) |
Income taxes - Schedule of Comp
Income taxes - Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Current: | |||
U.S. | $ 65 | $ (11,898) | $ (6,143) |
Non-U.S. | 6,211 | 10,192 | 4,405 |
Total current | 6,276 | (1,706) | (1,738) |
Deferred: | |||
Non-U.S. | 0 | 0 | 144 |
Total deferred | 0 | 0 | 144 |
Total income tax provision | $ 6,276 | $ (1,706) | $ (1,594) |
Income taxes - Reconciliation o
Income taxes - Reconciliation of Provision for Income Taxes (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Income Tax Disclosure [Abstract] | |||
Income (loss) before income taxes | $ (52,075) | $ 18,102 | $ (8,824) |
U.S. statutory income tax rate | 21.00% | 21.00% | 21.00% |
Notional U.S. federal income taxes at statutory rate | $ (10,936) | $ 3,801 | $ (1,853) |
Foreign taxes rate differential | 14,651 | 4,024 | (4,216) |
Share based compensation | (12,669) | (6,190) | (26,528) |
Change in valuation allowance | 11,643 | 6,821 | 244,344 |
Return to provision true-ups | 2,416 | 654 | (5,204) |
Research and Development Credits | (2,216) | (5,243) | (2,333) |
State income taxes | 1,572 | 607 | (16,679) |
Withholding Taxes | 273 | 2,366 | 384 |
Non-deductible expenses | (147) | 260 | 357 |
Unamortized intangible assets | 0 | 0 | (189,410) |
2020 Cares Act | 0 | (8,694) | 0 |
Other | 1,689 | (112) | (456) |
Total income tax provision | $ 6,276 | $ (1,706) | $ (1,594) |
Effective tax rate | (12.10%) | (9.40%) | 18.10% |
Income taxes - Schedule of Sign
Income taxes - Schedule of Significant Components of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Deferred tax assets: | ||
Unamortized intangible assets | $ 138,978 | $ 157,930 |
Impact of revenue recognition | 112,251 | 131,395 |
Net operating loss carryforwards | 77,664 | 40,314 |
Share based compensation | 25,644 | 17,595 |
Research and development | 12,146 | 9,186 |
Interest limitations | 7,948 | 6,975 |
Lease liability | 4,836 | 1,006 |
Other temporary differences | 3,032 | 2,822 |
Total gross deferred tax assets | 382,499 | 367,223 |
Less: valuation allowance | (375,717) | (364,082) |
Total deferred tax assets | 6,782 | 3,141 |
Deferred tax liabilities: | ||
Right of use assets | 4,559 | 936 |
Fixed assets | 2,214 | 2,185 |
Other liabilities | 9 | 20 |
Total gross deferred tax liabilities | 6,782 | 3,141 |
Net deferred taxes assets (liability) | $ 0 | $ 0 |
Income taxes - Additional Infor
Income taxes - Additional Information (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Income Taxes [Line Items] | |||
Non-U.S NOLs | $ 790,668 | ||
U.S. federal NOLs | 98,120 | ||
U.S. state NOLs | 124,146 | ||
Uncertain tax positions, interest and penalties recognized | 5 | $ 21 | $ 13 |
Swiss Federal Tax Administration (FTA) | |||
Income Taxes [Line Items] | |||
Non-U.S NOLs | 783,347 | ||
Foreign Tax Authority | |||
Income Taxes [Line Items] | |||
NOLs carry forwards indefinitely | 1,968 | ||
Foreign Tax Authority | Swiss Federal Tax Administration (FTA) | |||
Income Taxes [Line Items] | |||
Non-U.S NOLs | 405,553 | ||
State and Local Jurisdiction | |||
Income Taxes [Line Items] | |||
NOLs carry forwards indefinitely | 24,263 | ||
State and Local Jurisdiction | Swiss Federal Tax Administration (FTA) | |||
Income Taxes [Line Items] | |||
Non-U.S NOLs | $ 377,794 |
Income taxes - Schedule of Reco
Income taxes - Schedule of Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Reconciliation of uncertain tax benefits | |||
Balance at beginning of the year | $ 297 | $ 116 | $ 103 |
Reductions for taxes positions related to prior years | (143) | ||
Additions for taxes positions related to prior years | 181 | 13 | |
Balance at the end of the year | $ 154 | $ 297 | $ 116 |
Share capital - Schedule of Sha
Share capital - Schedule of Share Capital (Details) - shares | Dec. 31, 2021 | Dec. 31, 2020 |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract] | ||
Ordinary shares issued (in shares) | 103,971,263 | 102,334,276 |
Ordinary shares outstanding (in shares) | 103,971,263 | 102,334,276 |
Share capital - Additional Info
Share capital - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands | Dec. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 |
Share Capital [Line Items] | ||||
Unrecognized compensation cost | $ 96,379 | $ 96,379 | ||
Unrecognized compensation cost expected recognition weighted average period | 2 years 7 months 17 days | |||
Weighted average grant date exercise price of options granted (in usd per share) | $ 149.96 | $ 71.87 | $ 50.45 | |
Weighted average grant date fair values options forfeited and cancelled (in usd per share) | $ 62.77 | $ 22.98 | $ 22.11 | |
Aggregate intrinsic values options exercised | $ 143,695 | $ 156,910 | $ 266,626 | |
Fair value of ordinary shares (in usd per share) | $ 75.08 | $ 75.08 | $ 173.04 | $ 84.27 |
ESPP | ||||
Share Capital [Line Items] | ||||
Ordinary shares available for grant (in shares) | 4,954,997 | 4,954,997 | ||
Percentage of increase in shares outstanding | 1.00% | |||
Ordinary shares | ||||
Share Capital [Line Items] | ||||
Ordinary shares issued for ESPP (in shares) | 51,370 | 66,691 | 67,366 | |
Ordinary shares | ESPP | ||||
Share Capital [Line Items] | ||||
Ordinary shares issued for ESPP (in shares) | 51,370 | |||
2015 Plan | ||||
Share Capital [Line Items] | ||||
Percentage increase in number of shares available for issuance | 4.00% | |||
Number of shares available for issuance (in shares) | 39,264,853 | 39,264,853 | 35,107,569 | |
Ordinary shares available for grant (in shares) | 18,581,409 | 18,581,409 | ||
Options | ||||
Share Capital [Line Items] | ||||
Stock awards granted, vesting period | 4 years | |||
Options | 2015 Plan | ||||
Share Capital [Line Items] | ||||
Stock awards granted, expiration period | 10 years | |||
Restricted share units | ||||
Share Capital [Line Items] | ||||
Stock awards granted, vesting period | 3 years | |||
Restricted share units | 2015 Plan | ||||
Share Capital [Line Items] | ||||
Stock awards granted, vesting period | 3 years | |||
PSUs | 2015 Plan | Minimum | ||||
Share Capital [Line Items] | ||||
Stock awards granted, vesting period | 3 years | |||
PSUs | 2015 Plan | Maximum | ||||
Share Capital [Line Items] | ||||
Stock awards granted, vesting period | 6 years |
Share capital - Schedule of Fai
Share capital - Schedule of Fair Value Assumptions Used Only for Equity Based Awards Estimated Using Black-Scholes Option Pricing Model (Details) | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Dividend yield | 0.00% | ||
ESPP | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Expected term (years) | 6 months | 6 months | 6 months |
Dividend yield | 0.00% | 0.00% | 0.00% |
ESPP | Minimum | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Expected volatility | 54.00% | 47.00% | 44.00% |
Risk-free interest rate | 0.05% | 0.17% | 2.10% |
ESPP | Maximum | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Expected volatility | 81.00% | 66.00% | 62.00% |
Risk-free interest rate | 0.09% | 1.57% | 2.51% |
Stock Option Plans | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Dividend yield | 0.00% | 0.00% | 0.00% |
Stock Option Plans | Minimum | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Expected term (years) | 5 years 6 months | 5 years 6 months | 5 years 6 months |
Expected volatility | 60.00% | 54.00% | 55.00% |
Risk-free interest rate | 0.78% | 0.30% | 1.73% |
Stock Option Plans | Maximum | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Expected term (years) | 6 years | 6 years | 6 years |
Expected volatility | 63.00% | 56.00% | 61.00% |
Risk-free interest rate | 1.27% | 0.86% | 2.40% |
Share capital - Schedule of Sto
Share capital - Schedule of Stock Options to Purchase Ordinary Shares (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Number of options | |||
Number of options, outstanding at beginning of year (in shares) | 9,220,326 | ||
Number of options, granted (in shares) | 466,360 | ||
Number of options, exercised (in shares) | (1,016,369) | ||
Number of options, forfeited and cancelled (in shares) | (120,995) | ||
Number of options, outstanding at end of year (in shares) | 8,549,322 | 9,220,326 | |
Number of options, exercisable options (in shares) | 5,145,149 | ||
Weighted average exercise price | |||
Weighted average exercise price, outstanding at beginning of year (in usd per share) | $ 26.21 | ||
Weighted average exercise price, granted (in usd per share) | 149.96 | $ 71.87 | $ 50.45 |
Weighted average exercise price, exercised (in usd per share) | 20.81 | ||
Weighted average exercise price, forfeited and cancelled (in usd per share) | 62.77 | ||
Weighted average exercise price, outstanding at end of year (in usd per share) | 33.09 | $ 26.21 | |
Weighted average exercise price, exercisable options (in usd per share) | $ 19.76 | ||
Aggregate intrinsic value | |||
Aggregate intrinsic value, outstanding | $ 394,997 | ||
Aggregate intrinsic value, exercisable options | $ 285,295 |
Share capital - Schedule of RSU
Share capital - Schedule of RSUs and PSUs (Details) $ / shares in Units, $ in Thousands | 12 Months Ended |
Dec. 31, 2021USD ($)$ / sharesshares | |
RSUs/PSUs | |
Number of RSUs/PSUs | |
Unvested at beginning of year (in shares) | 4,466,151 |
Granted (in shares) | 632,275 |
Vested (in shares) | (569,248) |
Forfeited and cancelled (in shares) | (70,071) |
Unvested at end of year (in shares) | 4,459,107 |
Weighted average grant date fair value price | |
Unvested at beginning of year (in usd per share) | $ / shares | $ 54.06 |
Granted (in usd per share) | $ / shares | 138.37 |
Vested (in usd per share) | $ / shares | 52.63 |
Forfeited and cancelled (in usd per share) | $ / shares | 94.41 |
Unvested at end of year (in usd per share) | $ / shares | $ 65.56 |
Aggregate intrinsic value | |
Unvested at end of year | $ | $ 334,790 |
PSUs | |
Aggregate intrinsic value | |
Number of PSUs (in shares) | 3,029,835 |
Total fair value at grant date | $ | $ 161,885 |
PSUs | Tranche One | |
Aggregate intrinsic value | |
Number of PSUs (in shares) | 2,703,852 |
Fair value at grant date per PSU (in usd per share) | $ / shares | $ 48.16 |
Total fair value at grant date | $ | $ 130,218 |
PSUs | Tranche Two | |
Aggregate intrinsic value | |
Number of PSUs (in shares) | 108,113 |
Fair value at grant date per PSU (in usd per share) | $ / shares | $ 69.37 |
Total fair value at grant date | $ | $ 7,500 |
PSUs | Tranche Three | |
Aggregate intrinsic value | |
Number of PSUs (in shares) | 17,712 |
Fair value at grant date per PSU (in usd per share) | $ / shares | $ 84.68 |
Total fair value at grant date | $ | $ 1,500 |
PSUs | Tranche Four | |
Aggregate intrinsic value | |
Number of PSUs (in shares) | 10,532 |
Fair value at grant date per PSU (in usd per share) | $ / shares | $ 94.94 |
Total fair value at grant date | $ | $ 1,000 |
PSUs | Tranche Five | |
Aggregate intrinsic value | |
Number of PSUs (in shares) | 189,626 |
Fair value at grant date per PSU (in usd per share) | $ / shares | $ 114.26 |
Total fair value at grant date | $ | $ 21,667 |
Share capital - Equity-Based Co
Share capital - Equity-Based Compensation Expenses Related to Company's Equity-Based Awards (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total share-based compensation expense | $ 94,900 | $ 75,721 | $ 52,416 |
Cost of revenues | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total share-based compensation expense | 3,471 | 2,221 | 2,231 |
Research, development and clinical studies | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total share-based compensation expense | 27,597 | 18,125 | 7,570 |
Sales and marketing | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total share-based compensation expense | 22,673 | 17,672 | 11,897 |
General and administrative | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total share-based compensation expense | $ 41,159 | $ 37,703 | $ 30,718 |
Share capital - Schedule of S_2
Share capital - Schedule of Stock Option Outstanding (Details) - $ / shares | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Number of options outstanding (in shares) | 8,549,322 | 9,220,326 |
Options outstanding, weighted average remaining contractual term | 5 years 11 months 19 days | |
Number of options exercisable (in shares) | 5,145,149 | |
Options exercisable, weighted average remaining contractual term | 5 years 2 months 26 days | |
0.00 - 10.00 | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Number of options outstanding (in shares) | 1,116,075 | |
Options outstanding, weighted average remaining contractual term | 4 years 5 months 23 days | |
Number of options exercisable (in shares) | 1,116,075 | |
Options exercisable, weighted average remaining contractual term | 4 years 5 months 23 days | |
0.00 - 10.00 | Minimum | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Exercise price (in usd per share) | $ 0 | |
0.00 - 10.00 | Maximum | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Exercise price (in usd per share) | $ 10 | |
10.01 - 20.00 | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Number of options outstanding (in shares) | 2,668,814 | |
Options outstanding, weighted average remaining contractual term | 4 years 11 months 8 days | |
Number of options exercisable (in shares) | 1,787,295 | |
Options exercisable, weighted average remaining contractual term | 4 years 8 months 26 days | |
10.01 - 20.00 | Minimum | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Exercise price (in usd per share) | $ 10.01 | |
10.01 - 20.00 | Maximum | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Exercise price (in usd per share) | $ 20 | |
20.01 - 30.00 | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Number of options outstanding (in shares) | 1,886,852 | |
Options outstanding, weighted average remaining contractual term | 5 years 6 months 10 days | |
Number of options exercisable (in shares) | 1,461,424 | |
Options exercisable, weighted average remaining contractual term | 5 years 4 months 6 days | |
20.01 - 30.00 | Minimum | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Exercise price (in usd per share) | $ 20.01 | |
20.01 - 30.00 | Maximum | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Exercise price (in usd per share) | $ 30 | |
30.01 - 40.00 | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Number of options outstanding (in shares) | 331,417 | |
Options outstanding, weighted average remaining contractual term | 6 years 6 months 21 days | |
Number of options exercisable (in shares) | 272,217 | |
Options exercisable, weighted average remaining contractual term | 6 years 6 months 14 days | |
30.01 - 40.00 | Minimum | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Exercise price (in usd per share) | $ 30.01 | |
30.01 - 40.00 | Maximum | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Exercise price (in usd per share) | $ 40 | |
40.01 - 60.00 | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Number of options outstanding (in shares) | 1,200,783 | |
Options outstanding, weighted average remaining contractual term | 7 years 3 months 14 days | |
Number of options exercisable (in shares) | 274,740 | |
Options exercisable, weighted average remaining contractual term | 7 years 2 months 15 days | |
40.01 - 60.00 | Minimum | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Exercise price (in usd per share) | $ 40.01 | |
40.01 - 60.00 | Maximum | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Exercise price (in usd per share) | $ 60 | |
60.01 - 100.00 | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Number of options outstanding (in shares) | 871,555 | |
Options outstanding, weighted average remaining contractual term | 8 years 2 months 4 days | |
Number of options exercisable (in shares) | 227,804 | |
Options exercisable, weighted average remaining contractual term | 8 years 1 month 17 days | |
60.01 - 100.00 | Minimum | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Exercise price (in usd per share) | $ 60.01 | |
60.01 - 100.00 | Maximum | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Exercise price (in usd per share) | $ 100 | |
100.01 - 160.00 | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Number of options outstanding (in shares) | 462,606 | |
Options outstanding, weighted average remaining contractual term | 9 years 3 months | |
Number of options exercisable (in shares) | 5,594 | |
Options exercisable, weighted average remaining contractual term | 8 years 10 months 6 days | |
100.01 - 160.00 | Minimum | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Exercise price (in usd per share) | $ 100.01 | |
100.01 - 160.00 | Maximum | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Exercise price (in usd per share) | $ 160 | |
160.01 - 220.00 | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Number of options outstanding (in shares) | 11,220 | |
Options outstanding, weighted average remaining contractual term | 9 years 5 months 1 day | |
Number of options exercisable (in shares) | 0 | |
Options exercisable, weighted average remaining contractual term | 0 years | |
160.01 - 220.00 | Minimum | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Exercise price (in usd per share) | $ 160.01 | |
160.01 - 220.00 | Maximum | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Exercise price (in usd per share) | $ 220 |
Financial expenses, net (Detail
Financial expenses, net (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Financial expenses: | |||
Interest expense | $ (101) | $ (13,068) | $ (13,718) |
Revolving credit facility fee | (588) | (79) | 0 |
Amortization of discount and issuance costs | (3,339) | (4,514) | (156) |
Foreign currency transaction losses | (4,032) | 0 | (431) |
Others | (779) | (389) | (338) |
Financial expenses | (8,839) | (18,050) | (14,643) |
Financial income: | |||
Amortization of investments premium | 306 | 1,316 | 2,331 |
Foreign currency transaction gains | 0 | 2,648 | 0 |
Interest income | 791 | 1,787 | 4,402 |
Financial income | 1,097 | 5,751 | 6,733 |
Total financial expenses, net | $ (7,742) | $ (12,299) | $ (7,910) |
Basic and diluted net income _3
Basic and diluted net income (loss) per share (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 12 Months Ended | |||||||||||||
Dec. 31, 2021 | Sep. 30, 2021 | Jun. 30, 2021 | Mar. 31, 2021 | Dec. 31, 2020 | Sep. 30, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Dec. 31, 2019 | Sep. 30, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items] | |||||||||||||||
Net income (loss) attributable to ordinary shares as reported | $ (26,458) | $ (13,124) | $ (14,641) | $ (4,128) | $ 4,917 | $ 9,284 | $ 1,655 | $ 3,952 | $ 4,260 | $ 1,930 | $ (1,270) | $ (12,150) | $ (58,351) | $ 19,808 | $ (7,230) |
Net income (loss) used in computing basic net income (loss) per share | (58,351) | 19,808 | (7,230) | ||||||||||||
Adjustment needed in calculating diluted net income (loss) per share | 0 | 0 | 0 | ||||||||||||
Net income (loss) used in computing diluted net income (loss) per share | $ (58,351) | $ 19,808 | $ (7,230) | ||||||||||||
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares) | 103,884,288 | 103,731,147 | 103,484,866 | 102,633,545 | 101,945,085 | 101,234,306 | 100,718,893 | 99,877,567 | 99,226,445 | 98,485,519 | 96,356,317 | 94,811,282 | 103,433,274 | 100,930,866 | 97,237,549 |
Potentially dilutive shares that were excluded from the computation of basic net income (loss) per share: | |||||||||||||||
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares) | 103,884,288 | 103,731,147 | 103,484,866 | 102,633,545 | 110,604,714 | 108,643,814 | 107,647,802 | 108,100,623 | 107,911,519 | 107,604,578 | 96,356,317 | 94,811,282 | 103,433,274 | 108,877,648 | 97,237,549 |
Weighted anti-dilutive shares outstanding which were not included in the diluted calculation (in shares) | 8,524,922 | 1,307,762 | 10,230,982 | ||||||||||||
Basic net income (loss) per ordinary share (in usd per share) | $ (0.25) | $ (0.13) | $ (0.14) | $ (0.04) | $ 0.05 | $ 0.09 | $ 0.02 | $ 0.04 | $ 0.04 | $ 0.02 | $ (0.01) | $ (0.13) | $ (0.56) | $ 0.20 | $ (0.07) |
Diluted net income (loss) per ordinary share (in usd per share) | $ (0.25) | $ (0.13) | $ (0.14) | $ (0.04) | $ 0.04 | $ 0.09 | $ 0.02 | $ 0.04 | $ 0.04 | $ 0.02 | $ (0.01) | $ (0.13) | $ (0.56) | $ 0.18 | $ (0.07) |
Options | |||||||||||||||
Potentially dilutive shares that were excluded from the computation of basic net income (loss) per share: | |||||||||||||||
Share-based payment arrangements (in shares) | 0 | 6,967,554 | 0 | ||||||||||||
Restricted share units | |||||||||||||||
Potentially dilutive shares that were excluded from the computation of basic net income (loss) per share: | |||||||||||||||
Share-based payment arrangements (in shares) | 0 | 945,612 | 0 | ||||||||||||
ESPP | |||||||||||||||
Potentially dilutive shares that were excluded from the computation of basic net income (loss) per share: | |||||||||||||||
Share-based payment arrangements (in shares) | 0 | 33,616 | 0 |
Supplemental information - Sche
Supplemental information - Schedule of Long-lived assets by location (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Revenues from External Customers and Long-Lived Assets [Line Items] | ||
Long-lived assets | $ 35,616 | $ 22,625 |
United States | ||
Revenues from External Customers and Long-Lived Assets [Line Items] | ||
Long-lived assets | 23,263 | 11,868 |
Israel | ||
Revenues from External Customers and Long-Lived Assets [Line Items] | ||
Long-lived assets | 5,297 | 4,370 |
Switzerland | ||
Revenues from External Customers and Long-Lived Assets [Line Items] | ||
Long-lived assets | 4,085 | 2,849 |
Germany | ||
Revenues from External Customers and Long-Lived Assets [Line Items] | ||
Long-lived assets | 1,020 | 1,075 |
Japan | ||
Revenues from External Customers and Long-Lived Assets [Line Items] | ||
Long-lived assets | 799 | 1,230 |
Others | ||
Revenues from External Customers and Long-Lived Assets [Line Items] | ||
Long-lived assets | $ 1,152 | $ 1,233 |
Supplemental information - Sc_2
Supplemental information - Schedule of Revenues by geographic region (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |||||||||||||
Dec. 31, 2021 | Sep. 30, 2021 | Jun. 30, 2021 | Mar. 31, 2021 | Dec. 31, 2020 | Sep. 30, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Dec. 31, 2019 | Sep. 30, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Revenues from External Customers and Long-Lived Assets [Line Items] | |||||||||||||||
Net revenues | $ 133,213 | $ 133,606 | $ 133,517 | $ 134,695 | $ 143,953 | $ 132,660 | $ 115,925 | $ 101,828 | $ 99,234 | $ 92,062 | $ 86,713 | $ 73,309 | $ 535,031 | $ 494,366 | $ 351,318 |
United States | |||||||||||||||
Revenues from External Customers and Long-Lived Assets [Line Items] | |||||||||||||||
Net revenues | 353,110 | 340,782 | 232,805 | ||||||||||||
Germany | |||||||||||||||
Revenues from External Customers and Long-Lived Assets [Line Items] | |||||||||||||||
Net revenues | 93,939 | 93,264 | 86,564 | ||||||||||||
Other EMEA | |||||||||||||||
Revenues from External Customers and Long-Lived Assets [Line Items] | |||||||||||||||
Net revenues | 30,577 | 18,654 | 8,782 | ||||||||||||
Japan | |||||||||||||||
Revenues from External Customers and Long-Lived Assets [Line Items] | |||||||||||||||
Net revenues | 34,640 | 29,076 | 17,912 | ||||||||||||
Greater China | |||||||||||||||
Revenues from External Customers and Long-Lived Assets [Line Items] | |||||||||||||||
Net revenues | $ 22,765 | $ 12,590 | $ 5,255 |
Selected quarterly financial _3
Selected quarterly financial information (Unaudited) - Summary of Selected quarterly financial information (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 12 Months Ended | |||||||||||||
Dec. 31, 2021 | Sep. 30, 2021 | Jun. 30, 2021 | Mar. 31, 2021 | Dec. 31, 2020 | Sep. 30, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Dec. 31, 2019 | Sep. 30, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Selected Quarterly Financial Information [Abstract] | |||||||||||||||
Net revenues | $ 133,213 | $ 133,606 | $ 133,517 | $ 134,695 | $ 143,953 | $ 132,660 | $ 115,925 | $ 101,828 | $ 99,234 | $ 92,062 | $ 86,713 | $ 73,309 | $ 535,031 | $ 494,366 | $ 351,318 |
Gross profit | 103,526 | 103,400 | 104,918 | 108,310 | 115,817 | 104,265 | 90,451 | 77,332 | 74,448 | 69,162 | 65,607 | 53,495 | 420,154 | 387,865 | 262,712 |
Operating income (loss) | (23,398) | (8,552) | (12,295) | (88) | 12,092 | 15,022 | 6,668 | (3,381) | 153 | 3,855 | 1,196 | (6,118) | (44,333) | 30,401 | (914) |
Net income (loss) | $ (26,458) | $ (13,124) | $ (14,641) | $ (4,128) | $ 4,917 | $ 9,284 | $ 1,655 | $ 3,952 | $ 4,260 | $ 1,930 | $ (1,270) | $ (12,150) | $ (58,351) | $ 19,808 | $ (7,230) |
Basic net income (loss) per ordinary share (in usd per share) | $ (0.25) | $ (0.13) | $ (0.14) | $ (0.04) | $ 0.05 | $ 0.09 | $ 0.02 | $ 0.04 | $ 0.04 | $ 0.02 | $ (0.01) | $ (0.13) | $ (0.56) | $ 0.20 | $ (0.07) |
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares) | 103,884,288 | 103,731,147 | 103,484,866 | 102,633,545 | 101,945,085 | 101,234,306 | 100,718,893 | 99,877,567 | 99,226,445 | 98,485,519 | 96,356,317 | 94,811,282 | 103,433,274 | 100,930,866 | 97,237,549 |
Diluted net income (loss) per ordinary share (in usd per share) | $ (0.25) | $ (0.13) | $ (0.14) | $ (0.04) | $ 0.04 | $ 0.09 | $ 0.02 | $ 0.04 | $ 0.04 | $ 0.02 | $ (0.01) | $ (0.13) | $ (0.56) | $ 0.18 | $ (0.07) |
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares) | 103,884,288 | 103,731,147 | 103,484,866 | 102,633,545 | 110,604,714 | 108,643,814 | 107,647,802 | 108,100,623 | 107,911,519 | 107,604,578 | 96,356,317 | 94,811,282 | 103,433,274 | 108,877,648 | 97,237,549 |